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A neuron is a fundamental unit of the nervous system. These cells are 
differentiated and are not readily replaced. They are extremely active and 
display high metabolic rates. Because of their high activity they are 
subjected to a large amount of DNA damage throughout their lives. The 
most genotoxic type of DNA damage is a break in both strands of DNA and 
there can be as many as 10 to 50 double-stranded breaks (DSBs) in every 
cell per day. Because of this, a high-fidelity DNA repair mechanism would 
seem critical for ensuring neuronal longevity. 
 
There are two main mechanisms in which DNA DSBs are repaired: 
homologous recombination repair (HRR) and non-homologous end joining 
(NHEJ). HRR is said to occur in proliferating cells, whereas NHEJ is said to 
occur in post-mitotic cells. HRR is a high-fidelity process that uses a 
homologous copy of damaged DNA, usually from a sister chromatid, as a 
template to achieve error-free repair. In contrast, NHEJ is an error-prone 
system that simply uses a resection/re-ligation method to join the two ends 
of DNA back together. Because neurons are post-mitotic, they are thought 
to be repaired by NHEJ. However, given their longevity and high levels of 
activity, it would seem essential that neurons repair DNA DSBs by an error-
free system.  
 
The goal of this study was to determine whether HRR occurs in post-mitotic 
neuronal cells. The cell line Neuro-2a (N2a) is a mouse derived 
neuroblastoma cell line. The first objective of this project was to determine 
a differentiation protocol for this cell line. It was found, through cell counting 
and EdU incorporation assays, that cells treated with media containing 1% 
foetal bovine serum (FBS) and 10 μM retinoic acid (RA), over the course of 
seven days, showed the greatest number of N2a cells entering a non-
proliferative state.  
 
The plasmids DR-GFP and I-SceI were amplified and purified by bacterial 
transformation and miniprep. Once the plasmids were purified, DR-GFP 
 
iii 
was transfected into N2a cells by lipofection. The DR-GFP plasmid is a 
vector that has been engineered to contain a non-functional full-length 
green fluorescent protein (GFP) gene with a 5’-premature stop codon/I-SceI 
recognition sequence. These transfected cells were then treated with 
puromycin, as the DR-GFP plasmid  contains a puromycin resistance gene, 
to generate a stable N2a-DRGFP cell line.  
 
Once stable integration of DR-GFP was achieved, the N2a-DRGFP cells 
were then transfected with the I-SceI plasmid. I-SceI restriction 
endonuclease encoded by the I-Scel plasmid, has no recognition sequence 
in the mouse genome, so the expression of I-SceI will induce a single DSB 
at the DR-GFP 5’-premature stop codon/I-SceI recognition site. The DR-
GFP vector contains a portion of the wild-type GFP sequence, so if HRR 
occurs after I-SceI expression, the GFP 5’- premature stop codon will be 
removed and a functional GFP protein will be detected by 
immunofluorescence.  
 
No fluorescence was observed after I-SceI transfection in proliferating cells. 
PCR amplification of a DR-GFP sequence from N2a-DRGFP cells showed 
that DR-GFP had not been stably integrated into N2a cells. Similarly, co-
transfection of I-SceI and DR-GFP into N2a cells also did not show any 
fluorescence. To determine possible causes for this result, plasmids were 
sequenced, and it was found that the DR-GFP sequence was incorrect. 
Because of this, no further experimentation of HRR in post-mitotic cells 
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1 Chapter 1 
Literature Review 
1.1 Neurons 
A neuron is the fundamental unit of the brain and nervous system. It is 
composed of a cell body or soma, a nucleus, dendrites, an axon, axon 
terminals, and a myelin sheath (Figure 1.1).  Dendrites receive messages 
in the form of electrochemical signals, which can be either inhibitory or 
excitatory [1]. The signals received by dendrites are sent to the soma, where 
the summation of these signals can either equate to an inhibitory or 
excitatory response [1]. An action potential is an excitatory response and it 
carries an electrical signal through the axon by depolarisation [2]. 
Depolarisation occurs due to the movement of sodium and potassium ions 
through gated ion channels [2]. To assist in the conduction of the electrical 
signal, specialised cells – Schwann cells in the peripheral nervous system 
(PNS) and oligodendrocytes in the central nervous system (CNS) – can 
wrap the axon with myelin. Polarity changes can thus occur at gaps within 
the myelination, called Nodes of Ranvier, as opposed to the whole axon, 
which allows faster and more efficient conduction of the action potential than 
occurs in unmyelinated axons [3]. At the distal end of the axon, the axon 
terminal, is capable of transmitting signals to other neurons [4]. Here, 
electrical signals conveyed by the axon are converted to chemical signals, 
in the form of neurotransmitters [4]. Neurons are connected by synapses, in 
which there is a small gap called a synaptic cleft where neurotransmitters 
diffuse across to allow the dendrites of post-synaptic neurons to receive the 
signal [4]. 
 
There are trillions of neurons in a human body, which form networks that 
communicate to each other with this form of electrochemical signalling to 
elicit responses. These networks are very intricate and can sometimes be 
very complex and create the nervous system. The nervous system can be 




PNS, which consists of all other nerves in the body. The CNS and PNS 
communicate with each other to send signals either through an efferent or 
afferent system [5]. The efferent system is the CNS sending signals to the 
body and controls two systems; the autonomic and somatic systems. The 
autonomic system controls involuntary muscles and systems such as 
breathing and digestion, whereas the somatic system controls voluntary 
movements such as waving and running. The afferent system sends 
sensory signals to the CNS from the body such as smell, taste, sound, pain, 












Figure 1.1 Labelled illustration of a neuronal cell [6] 
 
Neurons are highly metabolically active cells and because of this they are 
can sustain a large amount of DNA damage on a daily basis. 
  
1.2 DNA Damage 
There are different types of DNA damage that can occur in cells (Figure 1.2). 
These include single-base damage, modifications that distort the DNA 
double-helix, single-stranded breaks (SSBs), and double-stranded breaks 
(DSBs) [7]. Each form of DNA damage affects the integrity of the DNA, and 
therefore the cell, in a different way. DNA damage occurs by both 





DNA damage can arise from endogenous sources, such as metabolic 
processes that can create reactive oxygen or nitrogen species. For example, 
processes of mitochondrial respiration, DNA replication, DNA transcription, 
and V(D)J recombination that occurs in lymphocytes [8-10]. Reactive 
oxygen and nitrogen species are one of the main causes of DNA damage 
in the brain due to its high metabolic activity [7]. Exposure to UV light, 
ionising radiation, and chemotherapy agents are exogenous causes of DNA 
damage [7]. If damage is left unrepaired it can affect the integrity of the 
genome [11]. 
 
A bulky DNA adduct is where a segment of DNA is bound to a cancer-
causing chemical and are caused by exposure to polycyclic aromatic 
hydrocarbons (PAHs) [12]. If this damage is not repaired effectively, it can 
potentially lead to carcinogenesis [13].  
 
Intra-strand and inter-strand crosslinks can also occur in DNA. Endogenous 
and exogenous agents can react with nucleotides and cause covalent 
bonds to be formed either on the same strand of DNA (intra-strand 
crosslinking) or on opposite strands of DNA (inter-strand crosslinking) [14]. 
Inter-strand crosslinking is particularly toxic as it prevents transcription and 
replication by inhibiting strand separation [14], and can lead to a DSB. 
 
Single base damage is formed when a nucleotide within DNA is chemically 
damaged, which can be due to oxidation, alkylation, or deamination [15]. In 
addition, the nucleotide uracil can be inappropriately incorporated into DNA 
[15]. If single-base damage is not repaired, it can lead to a SSB in the DNA. 
 
Single-strand breaks are lesions that are formed in one strand of the DNA 
duplex. Single-strand breaks are the most common type of lesion that arises 
in cells [16]. This damage can cause an altered nucleotide sequence of the 
damaged DNA and can also lead to DSBs, which can affect the integrity of 





Double-strand breaks are the most genotoxic of all DNA damage [18]. DSBs 
are lesions that are formed when both strands of the DNA duplex are broken, 
and if not repaired, can cause apoptosis of the cell. If misrepaired, they can 
cause a loss of genetic information, mutations, and chromosomal 
rearrangement [7, 8, 11, 18, 19]. The main endogenous cause of DSBs is 
when a DNA replication fork encounters an unrepaired DNA lesion, which 
triggers the collapse of the fork [20]. 
 
Figure 1.2 Types of DNA damage [21] 
 
Because DNA damage can affect the genome in such a crucial way, DNA 
repair pathways are essential to protect the integrity of the cell.  
 
1.3 DNA Repair Mechanisms 
Because there is a wide variety of DNA damage that can occur, there are 
many DNA repair pathways, each with overlapping or different complexes 
and factors involved. The base excision repair (BER) pathway is responsible 
for repairing single base damage that does not distort the DNA helix [22]. 
The downstream steps of BER are also responsible for the repair of SSBs. 
The nucleotide excision (NER) pathway is responsible for repairing bulky 




is responsible for repairing insertions, deletions, and mis-incorporation of 
bases that can arise during DNA replication and recombination [24]. The 
double-strand break repair (DSBR) pathway is responsible for repairing 
double-strand breaks and inter-strand crosslinks [7]. DSBR pathways are 
crucial in a cell because the consequences that occur if a DSB is not 
repaired or misrepaired can be catastrophic.  
 
1.3.1 Double-Strand Break Response 
When a DSB occurs, a response is activated almost instantly, which is 
called the DSB response. The DSB response is a multi-tiered process that 
involves the rapid recruitment of “sensors” to the break site. H2AX is sensor 
and is a histone variant of the protein family H2A. H2AX is rapidly 
phosphorylated to form γH2AX following DNA damage. The 
phosphorylation of H2AX creates a euchromatin structure surrounding the 
break site which allows access to repair factors and checkpoint proteins [25]. 
The MRN complex (Mre11, RAD50, and Nbs1) is also a sensor and 
processes the free DNA ends after DNA damage and creates a signal 
cascade that activates “transducers” [26, 27]. Ataxia telangiectasia mutated 
(ATM) and DNA-dependent protein kinase, catalytic subunit (DNA-PKcs), 
are transducers that amplify signals to downstream effectors that are 
associated with DNA repair and are regulated by mediator proteins [8, 19, 
28]. There are two mediator proteins and their affinity to bind at the DSB 























Figure 1.3 DSB repair pathways 
 
The two main mechanisms by which DSBs are repaired are homologous 
recombination repair (HRR) and non-homologous end joining (NHEJ) 
pathways [7, 11] (Figure 1.3).  There is also an alternative pathway by which 
DSBs can be repaired called microhomology-mediated end joining (MMEJ) 
or alternative NHEJ (alt-NHEJ) [30]. The mechanism of this pathway is still 
actively being researched, but it uses micro-homologous sequences and is 
kinetically much slower than the classic NHEJ pathway [30]. This pathway 
is very error prone and often results in deletions, translocations, complex 
rearrangements and inversions [31].  
 
HRR is a complex, energy consuming but high-fidelity process based on 
homologous recombination where a homologous copy of the sequence, for 
example a sister chromatid, is used as a template to achieve error-free 




the MRN complex and CtIP. The MRN-CtIP complex resects DNA and 
generates a 3’ single stranded DNA (ssDNA). This ssDNA is then coated by 
Replication protein A (RPA), which removes the secondary structure [33]. 
BRCA2 then mediates the replacement of RPA with RAD51. Once RAD51 
is assembled it forms a nucleoprotein filament and promotes a search for a 
homologous sequence to use as a template for repair. Rad52, Rad54, and 
Rad51 paralogs (Xrcc2, Xrcc3, Rad51L2, Rad51L3) are also recruited to 
the lesion to facilitate strand invasion and recombination. After strand 
invasion and formation of the D-loop, the DNA end is extended using the 
homologous sequence as a template [34]. Both ends of the DSB are 
engaged and this can be by either independent strand invasion or by second 
end capture, which leads to double Holliday junction formation. The junction 
can be processed by a resolvase into non-crossover or crossover products 
[35]. 
 
NHEJ is a very simple system in comparison to HRR and can occur at any 
phase in the cell cycle but predominates in the G1 and G2 phase [7, 36, 37]. 
It functions by the use of a resection/re-ligation mechanism to put the two 
ends of DNA back together [7, 36, 37]. This is a very error-prone system, 
and crucial information can be lost due to small insertions, deletions, 
substitutions at the break site, and translocations if DSBs from differing 
parts of the genome are joined together [11, 36]. NHEJ is mediated by 
Ku70/Ku80 heterodimer, which forms a ring around the DNA DSB site [38]. 
Ku70/Ku80 then allows the recruitment of the DNA-PKcs. If the DNA ends 
are not able to be directly ligated the nucleases Artemis or Exo1 will then 
process the damaged DNA, and the DNA polymerases Polλ and Polµ will 
fill the gap [39]. When the DNA ends are matched, DNA ligase IV and 
cofactor Xrcc4 will mediate their ligation [40].   
 
HRR is believed to occur in proliferating cells, whereas NHEJ repair is 
believed to occur in post-mitotic cells [7, 11, 18]. HRR is a complex system 
that occurs in the S and G2/M phase of the cell cycle and uses a 
homologous copy of the DNA sequence, such as a sister chromatid, as a 




effective, but is energy and time-consuming; it takes hours to repair these 
breaks, compared to only 30 minutes in NHEJ [37]. 
 
The utilisation of a high-fidelity repair process such as HRR in proliferating 
cells makes sense as an error-prone system of repair could lead to a clonal 
expansion of a misrepaired genome if the DNA damage is not repaired 
accurately. In contrast, in post-mitotic cells, which do not divide, an error-
free repair process is thought to be less critical and NHEJ repair is sufficient; 
if the repair of the DSB introduces a deleterious mutation, the potentially 
expendable cell can be deleted through a process such as apoptosis without 
affecting the organism or future generations of cells.  
 
Because there is such a vast number of neurons in the human body and the 
networks which they form are extremely active [19], neurons are subjected 
to large amounts of DNA damage; up to 50 DSBs per cell per day have been 
reported [41]. Neurons are post-mitotic cells, so loss of these cells due to 
DNA damage can be very consequential. If DNA damage is left to 
accumulate it can cause DNA lesions, which in proliferating cells can lead 
to cancer, whereas in neurons it can lead to neurodegenerative pathologies 
[42]. Because it is crucial that neurons last for a life time, it would make 
sense for a higher fidelity repair process such as HRR to occur in these cells 
to maintain their integrity. 
 
1.3.3 Pathway Choice 
Pathway choice for a DSB is determined by mediator proteins and they differ 
between HRR and NHEJ. The affinity that these proteins have to the DNA 
break site determines which pathway will be selected for in the repair of 
DSBs [37]. The HRR pathway is mediated by Breast Cancer 1, early onset 
(BRCA1), while NHEJ is mediated by p53-binding protein (53BP1). There is 
a balance between these two mediators and their binding affinities affect 
each other. 53BP1 has been identified as a negative regulator of HRR as it 
limits the resection of DSBs and steers the repair towards the NHEJ 




NHEJ pathway as the processing guides the repair pathway towards HRR 
and prevents the binding of NHEJ repair factors [43]. 
 
Post-translational modifications (PTMs) play a prominent role in the binding 
affinity of these mediators and determines whether HRR or NHEJ 
mechanisms are used for the repair of DNA DSBs [8]. PTMs are also 
involved in many other aspects of the DSBR. 
 
1.4 Post-Translational Modifications  
Histones are a family of positively charged proteins that assist with packing 
negatively charged DNA into a condensed chromatin structure that allows 
DNA to fit into the nucleus of a cell. Nucleosomes are the basic subunit of 
chromatin and are comprised of approximately 146 bp of DNA wrapped 
around an octameric histone core, which is formed by histones H2A, H2B, 
H3, and H4. 
 
Histone modifications in the form of PTMs assist in the response to DNA 
damage. PTMs can occur on the C- or N- terminals of the histone tails. 
There are many types of PTMs that can occur in histones including: 
acetylation, methylation, phosphorylation, ubiquitination, and PolyADP-
ribosylation [8, 44]. These modifications can affect the DSB response at 
different phases which include: the detection of DSBs; the restoration of 
chromatin back to its condensed state once the DNA has been repaired; the 
regulation and accessibility of chromatin for repair factors and the binding 
of checkpoint proteins; and the activation of checkpoint signals [8]. 
 
1.4.1  Acetylation 
Histone acetyltransferases (HATs) add acetyl groups to histone tails, 
whereas histone deacetylases (HDACs) remove acetyl groups from histone 
tails. HATs and HDACs play an important role in the accessibility of 





It has been shown that acetylation of the histone H4K16 in chromatin 
surrounding the double-strand break-site inhibits the NHEJ pathway as it 
decreases the binding affinity of 53BP1 [45]. This allows for the binding of 
BRCA1 to the break-site which promotes HRR [45]. The acetylation of 
H4K16 allows for the regulation of the two pathways by controlling the 
binding affinity of mediators to the DNA break-site. 
 
The acetylation of lysine 56 on histone H3 (H3K56) occurs in high numbers 
in newly synthesised histone H3 molecules following the S phase of the cell 
cycle [46-48]. The acetylation of H3K56 declines throughout the cell cycle 
and is very low during the G2 phase; however, in the presence of DNA 
damage, acetylation of H3K56 remains high, which suggests that it is 
important in the DNA damage response [46-48]. The acetylation of H3K56 
creates a favourable environment for DNA repair as it allows access to DNA 
repair machinery by the relaxation of chromatin [46-50]. 
 
HDAC1 and HDAC2 are rapidly recruited to DNA damage sites where they 
deacetylase H4K16 and H3K56 [8, 51]. The deacetylation of H4K16 is 
important for repair via the NHEJ pathway, as it prevents BRCA1 from 
binding to the break site, and deficiency in HDAC1 and HDAC2 activity 
results in defective repair by NHEJ [51].  
 
1.4.2  Phosphorylation 
H2AX is a member of the histone H2A family. Phosphorylation of serine 139 
(S139) on H2AX plays an important role in the response to DNA damage. 
Within seconds of DNA damage, S139 on H2AX surrounding the DSB site 
is phosphorylated, followed by those further away from the break site (up to 
2 mb) [46]. The levels of phosphorylated H2AX (γH2AX) are reflective of the 
total DSBs within a cell. The phosphorylation of H2AX creates a 
euchromatin structure surrounding the break site, which allows access to 
repair factors and checkpoint proteins [25]. This allows the DNA DSBs to be 






ATM and DNA-PKcs are responsible for the phosphorylation of H2AX. 
These proteins are both part of the phosphoinositide 3-kinases (PI-3Ks) 
family and they act to repair damage. ATM and DNA-PKcs sense and bind 
to the DNA break site, which leads to their activation and the subsequent 
phosphorylation of H2AX around the break site [52, 53]. Histone H2AX is 
also dephosphorylated at tyrosine 142 (H2AX Y142) and is important for the 
formation maintenance of γH2AX at the site of the DSB [25]. It also acts to 
recruit repair factors for the repair of the DSB [54, 55]. After the DSB is 
repaired it is important for the removal of γH2AX to condense the chromatin 
once again. This can be achieved by γH2AX being removed from chromatin 
by histone exchange or dephosphorylated by protein phosphatase 2A 
(PP2A) [56]. 
 
1.4.3  Ubiquitination 
The E3 ubiquitin ligases, RNF8 and RNF168, play a key role in the 
promotion and accumulation of DNA repair factors to the DNA DSB site [57]. 
RNF8 and RNF168 ubiquitylate specific marks on histone H2A, which is 
essential for DSB repair [57] .  
 
When H2AX is phosphorylated it allows for MDC1 protein to bind to the DNA 
break site [58]. MDC1 acts as a scaffold protein that recruits other DNA 
repair factors to the site of DNA damage [58, 59]. This includes RNF8 and 
RNF168. This binding allows RNF8 and RNF168 to ubiquitylate marks on 
histone H2A, near the DSB site [60]. These ubiquitin marks allow further 
proteins and factors associated with the damage response to bind and help 
repair DNA damage [60].   
 
1.4.4  Methylation 
Histone methyltransferases (HMTs) are responsible for the transfer of 
methyl- groups from S-adenosylmethionine (SAM) to histones. Histone 
demethylases (HDMs) are responsible for the removal of these methyl 




methylated in response to DNA damage.  Lysine residues on histones H3 
and H4 can be either mono-, di- or tri- methylated (me1, me2, me3, 
respectively) in response to DNA damage.  
 
Methylation of lysine 20 of histone H4 (H4K20) is known to be involved in 
the DNA damage response. H4K20me1 and H4K20me2 are involved with 
DNA replication and DNA damage repair, whereas H4K20me3 is associated 
with the silencing of the heterochromatic region [61]. H4K20 is always in a 
methylated state but it is not often detected due to the heterochromatin 
structure of a cell when it is not stressed. However, in a stressed state the 
chromatin is loosened, thus the methylation mark can be detected. Mono- 
and di-methylated H4K20 allows 53BP1 to bind to the site of the damage 
[62].  
 
Methylated lysine 79 of histone H3 (H3K79) is another example of a histone 
protein that is always in a methylated state but is not detected due to the 
heterochromatic structure of the chromatin in an unstressed cell. When the 
cell becomes stressed and the chromatin is loosened, this methylation mark 
can be detected and allows 53BP1 to be recruited [63]. 53BP1 is the 
mediator for the NHEJ pathway, so H4K20 and H3K79 are both positive 
regulators of the NHEJ pathway. These proteins work together to ensure 
that 53BP1 is recruited to the break site [63]. 
 
1.4.5  Poly ADP-Ribosylation 
PolyADP-ribosylation (PARylation) regulates DNA repair, chromatin 
organisation, transcription, and replication. It is the process in which 
polymers of ADP-ribose are transferred from the co-substrate nictonamide 
adenine dinucleotide (NAD+) to proteins that have specific amino acid side 
chains that can accept the ADP-ribose moiety. Enzymes called poly (ADP-
ribose) polymerase (PARP) are responsible for this transfer.  
 
PARP-1 is the most abundant PARP family member and it is involved in 




This allows for recruitment of chromatin remodelling factors, such as NuRD 
and ALC1, which are essential for the DNA repair process [64].  
 
PARP-1 can also function as an alternative pathway to the NHEJ pathway. 
PARP-1 can bind directly to DNA and compete with Ku [65]. However, Ku 
has a higher binding affinity to damaged DNA, so will preferentially bind to 
DNA DSBs. PARP-1 is a back-up repair pathway to the NHEJ pathway, if 
the repair factors for NHEJ are not available [65]. 
 
1.4.6 Summary of Post-Translational Modifications 
The PTMs that occur in neurons following a DSB are essential, as they 
restructure the chromatin, and recruit repair factors and checkpoint proteins, 
to repair the DNA damage. This response happens within seconds to 
minutes of DNA damage and leads to  proficient repair of DNA damage. 
 
PTMs also play an important role in determining which DNA DSB repair 
pathway will be used, and thus determines the accuracy in which a DSB is 
repaired. The predominant PTM that determines the pathway is the 
acetylation of H4K16. Acetylation of H4K16 allows BRCA1 to bind to H4K16 
instead of 53BP1, which leads to the resection of the DSB and the HRR 
pathway is used. 
 
1.5  DNA Repair in Neurons 
The repair of DNA damage, especially DNA DSBs is essential in an 
organism, as unrepaired or misrepaired DSBs can affect the integrity of the 
genome and could potentially lead to neurodegenerative pathologies.  
 
The cell cycle plays a role in the repair pathway used. In the S and G2/M 
phase of the cell cycle, a homologous sequence available in the form of a 
sister chromatid, making HRR possible. Post-mitotic cells are either in the 
G0 or G1 phase of the cell cycle, where a homologous sequence is not 





Neurons are different to normal post-mitotic cells in the fact that they are not 
expendable cells. As such, the accumulation of lesions or deletion of cells 
due to insufficient DNA repair can lead to neurodegenerative pathologies.  
NHEJ is associated with the loss of crucial information due to small 
insertions, deletions, substitutions, and translocations at break sites [11, 36]. 
If neurons were to repair DSBs primarily by NHEJ it would be expected that 
DNA damage accumulation and deletion of cells would occur frequently. 
However, neurodegenerative diseases mainly affect the older population, 
with only a number of rare cases being early onset. Defective DDRs have 
been observed in neurodegenerative diseases. Neural defects show the 
importance of a functioning DDR and how defects in these pathways results 
in a wide range of disorders. 
 
Neurons do not need to repair themselves quickly for their short-term 
survival, but it is essential that they have a capacity to repair DNA damage 
to a sufficient level for long-term survival [19].  Neurons are critical cells in 
our body, and DNA lesions, if left to accumulate, can lead to 
neurodegeneration. It would make sense that a high-fidelity repair such as 
HRR would occur to protect the integrity of these cells. 
 
1.6 Neurodegenerative Diseases  
Evidence for neurons maintaining the capacity for high-fidelity repair come 
from investigations of neurodegenerative disease and injury.  The loss of 
neurons or accumulation of DNA lesions due to an inefficient or defective 
DDR can lead to a range of neurodegenerative diseases that cause 
problems with movement (ataxia) and mental functioning (dementia). These 
diseases are progressive in nature and do not have any known cures. 
 
1.6.1 Aging 
Aging is a major risk factor for neurodegeneration [66]. Neurons have 
extremely high activity, and as a consequence high rates of oxidative 
damage can occur. Oxidative damage is a major contributor to the 




disorders [8]. The “Free Radical Theory of Aging” hypothesises centres on 
oxidative damage, which, if left unrepaired, will contribute to the decline of 
cellular activities and age-related deterioration [67]. Deficiencies in the 
repair of DNA damage have been shown to increase with age, and this 
increase has been correlated with cognitive decline and neurodegeneration 
that is observed in the aged population [68]. It has also been found that the 
different brain regions accumulate DNA damage at differing rates, with the 
most damage in the brain being accumulated in the hippocampus and the 
cortex [8, 19]. This evidence is consistent with the cognitive and memory 
decline that is seen in neurodegenerative disorders. 
 
Some insights into the genetics of aging comes from progeroid syndromes, 
which include, but are not limited to, Werner Syndrome, Bloom syndrome, 
Xeroderma Pigmentosum, and Cockayne syndrome. 
 
Werner syndrome is one of the most studied progeroid syndromes as it 
mimics natural aging, but in a much shorter timeframe. It is an autosomal 
recessive disorder and results from mutation in the WRN protein, a RecQ 
helicase, which is involved in both NHEJ and HRR pathways. WRN interacts 
with the  Ku70/80, DNA-PKcs, XRCC4 and DNA ligase IV  proteins involved 
in NHEJ [69-71] and with NBS1, which is a part of the MRN complex that is 
involved in HRR [72]. Mutation may result in truncation of WRN, and a 
reduction in DNA repair [73]. There is also a down-regulation of the p53 
checkpoint protein, that results in a loss of p53-dependent apoptosis, which 
means that dysfunctional cells will have a higher survival rate [74]. These 
mutations contribute to the phenotypes observed in WS, which include; 
wrinkling of skin, skin atrophy, growth retardation, greying of hair, hair loss, 
prematurely aged faces, loss of fat tissue, and premature aging of the brain 
[75, 76]. 
 
There have been some epigenetic marks that have been linked with the 
process of aging. The dysregulation of the acetylation of H4K16, which is 
important for the HRR pathway, has shown to be involved in the aging 




and deficiency in the DNA repair process [77, 78]. γH2AX, the marker for 
unrepaired DNA damage, can be used to observe aging. There are two 
types of γH2AX that can be found in cells and these are: transient γH2AX 
foci, and residual γH2AX foci [79]. Transient γH2AX are associated with the 
fast and efficient repair of DNA DSBs, which usually occurs within minutes 
to hours from the occurrence of the DSB [79]. Residual γH2AX on the other 
hand, usually can persist for months to years after the occurrence of a DSB 
and this can be for one of two reasons; either the DSB is slow to repair, or 
the DSB will remain permanently unrepaired due to either cellular 
senescence, apoptosis, or because the DSB is on part of the genome that 
cannot be repaired, such as on telomeres [79-83]. γH2AX and its 
accumulation due to unrepaired DNA damage has been implicated in 
diseases that have accelerated aging, such as Werner’s syndrome, and 
Alzheimer’s disease [84, 85]. 
 
1.6.2 Alzheimer’s Disease 
Alzheimer’s disease (AD) is the most common progressive 
neurodegenerative disorder, characterised by severe dementia. It mainly 
affects those over 65 years of age, with 90-95% of those diagnosed being 
in this age range [86]. The symptoms of AD include memory loss, cognitive 
decline, and behavioural changes [87]. The later stages of AD also include 
symptoms of reduced co-ordination and mobility, and tremors [87]. 
Neuropathologically, patients exhibit extracellular senile plaques that 
consist of amyloid-β peptide, intra-neuronal neuro fibrillary tangles (NFT), 
degeneration of synapses, and neuronal cell death [86, 87].  
 
In 1990, it was first shown that DNA strand breaks can be increased by 2-
fold in the brain of AD patients compared to controls [88]. In AD patients, 
there is an observed increase in DSBs and a decrease in DSBR proteins, 
such as DNA-PKcs and the MRN complex [89, 90]. Recently, it has been 
shown in mice that are transgenic for human APP – a model for AD – have 




baseline, and there are further increases of DSBs in these transgenic mice 
when exploring a novel environment [91].  
 
1.6.3 Parkinson’s Disease 
Parkinson’s disease (PD) is a sporadic, progressive, neurodegenerative 
disease characterized by loss of dopaminergic neurons in the substantia 
nigra. PD affects motor function, with symptoms including tremors, 
bradykinesia, and stiffness [92]. The mechanisms of cell death in PD are 
not well understood, but DNA damage has been implicated with this disease. 
In a study using post-mortem brains from 5 confirmed cases of PD and 6 
age-matched controls, DNA from PD brains showed that the midbrain, 
caudate nucleus/putamen, thalamus, and hippocampus had more DNA 
DSBs than healthy aged-matched controls [93].  
 
1.6.4 Amyotrophic Lateral Sclerosis 
Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disorder that 
affects motor neurons, which are responsible for voluntary movement. It 
affects mainly those between the ages of 55-75 years. The upper and lower 
motor neurons both begin to degenerate and die, which leads to the 
symptoms observed [94-96]. Symptoms are progressive: at first muscles 
begin to weaken until they start to atrophy, and patients eventually lose 
control over their muscles, which makes it almost impossible to walk, talk, 
eat, and eventually breathe. Patients often die within five years of the 
symptoms occurring, often from respiratory failure [95]. 
 
There are two types of ALS that are observed, familial ALS (fALS), which 
accounts for up to 10% of cases observed, and sporadic ALS (sALS), which 
accounts for 90% or more of cases observed [97]. The exact mechanisms 
in which the degeneration of the motor neurons that is observed in ALS are 
not known. However, around 20% of all fALS cases are caused by a 
mutation in copper-zinc superoxide dismutase 1 (SOD1) [97]. Both SSBs 
and DSBs were detected in motor neurons of transgenic mice for the human 





The studies of the motor cortex in post-mortem brains of ALS patients 
showed that there was an increase of oxidative DNA damage repair activity 
[99]. DNA damage was suggested to occur upstream of the motor neuron 
degeneration that occurs in this disease. 
 
1.6.5 Summary of Neurodegenerative Diseases 
As can be seen from these examples, with neuropathological conditions, 
neurons accumulate greater amounts of DNA damage. There is also 
evidence that non-repaired or misrepaired DNA DSBs contributing to the 
neurodegenerative pathologies that have been stated in this section. 
 
1.7 Neurological Defects with DNA Repair Mutations 
Evidence for neurons maintaining a high-fidelity mechanism of repair also 
comes from investigations into mutant DNA repair proteins – in all known 
conditions in which a DNA repair protein is dysfunctional (and not embryonic 
lethal), a neurological phenotype is present. 
 
Defects due to mutant DNA repair proteins are early onset and are often 
progressive in nature. These defects play an important role in determining 
the key factors involved in the DDR and the role that they play. 
 
1.7.1 Ataxia-Telangiectasia 
Ataxia-telangiectasia (A-T) is a monogenic disease that is caused due to 
mutation in the ATM gene [100]. This mutation causes the inactivation or 
the loss of the gene [101]. ATM is present throughout the DNA damage 
response, by phosphorylating key proteins, which can lead to either DNA 
repair or apoptosis of the damaged cell [26]. Because ATM is diverse in its 
functionality, the loss or inactivation of this protein causes many different 
phenotypes which include: ataxia, telangiectasia, radiosensitivity, 




associated with disease [102]), immunodeficiency, and chromosomal 
translocations [101]. 
 
A-T is an early onset, progressive, neurodegenerative disorder. Infants 
appear normal, but at two to three years of age, ataxia begins to appear and 
commonly progresses to the child being wheelchair bound by the age of 8 
to 12 [101, 103]. By MRI, the cerebellum of patients often appears normal 
following diagnosis with A-T, but declines in mass significantly by the age of 
10 [101]. Because A-T patients are immunodeficient and have a 
susceptibility to cancer, they have a significantly shortened lifespan, with 
the percent of survival of those who have A-T rapidly declining to only a very 
small percentage by the time they reach thirty years old [104]. Similarly, 
ATM knock-out mice show ataxia, growth retardation, immunodeficiency, 
meiotic failure, and predisposition to cancer [105], similar to that of ATM in 
humans.  
 
1.7.2 Ataxia-Telangiectasia-Like Disorder 
Ataxia-telangiectasia-like disorder (ATLD) is a very rare disorder, which 
shares many similarities with A-T. ATLD is caused by a hypomorphic 
mutation in the MRE11 gene, which results in a deficiency of the MRE11 
protein, with the protein either truncated or full-length and mutant [106, 107]. 
MRE11 complexes with RAD50 and NBS1, to form MRN, which initially 
processes DNA DSBs before HRR or NHEJ repair pathways are activated. 
 
ATLD shows progressive cerebellar ataxia, and progressive 
neurodegeneration of the cerebellum, as A-T does; however, unlike A-T, 
ATLD is not associated with telangiectasia, immune deficiency, and there 
are no reports of cancer [107]. ATLD also has a later onset than A-T and a 
slower progression of the disorder, which makes it a less severe condition 
than A-T in the early years [107]. The mutations in the MRE11 gene are 
hypomorphic, as knock-out mice for the MRE11 gene results in early 





1.7.3 Nijmegen Break Syndrome 
Nijmegen break syndrome (NBS) is caused by mutation of NBS1, which 
results in defective NBS1 protein [107, 109]. NBS1 is also part of the MRN 
complex but has a very different phenotype than ATLD. NBS is 
characterised by microcephaly, immunodeficiency, growth retardation and 
susceptibility to cancer [110]. There is no obvious neurodegeneration in this 
disorder.  
 
NBS1 mutations interfere with the DNA repair function, by causing 
hypersensitivity to DSBs, which is why microcephaly is observed, due to the 
huge increase in neuronal cells lost during development [87]. The mutations 
in the NBS1 gene are hypomorphic, as germline deletion is lethal during 
early embryonic development [111].  
 
1.7.4 Nijmegen Break Syndrome-Like Disorder  
There has been recent evidence that two germline mutations in the RAD50 
gene, gives rise to a low level of unstable RAD50, and results in a Nijmegen 
break syndrome-like disorder (NBSLD), which is similar to NBS except that 
there is no associated immunodeficiency [112].   
 
A RAD50 deficiency results in reduction of ATM autophosphorylation, and 
also an impaired radiation-induced phosphorylation of the target proteins of 
ATM [112]. It also affects the cell-cycle checkpoint proteins present in the 
G1 and S phase by impairing their function [112]. RAD50 deficiency also 
results in a decrease in the expression levels of NBS1 and MRE11, the 
components that form a complex with RAD50 to form MRN [112]. 
 
1.7.5 Summary of Neurological Defects 
Evidence for the neurological phenotypes that can occur due to a defective 
DDR resulting from mutant DNA repair proteins can be shown by the 
diseases/syndromes such as A-T, ATLD, NBS, NBSLD. Neurological 




importance of a high-fidelity repair mechanism for neuronal cells, such as 
HRR.  
 
As seen with many of the DNA DSB repair enzyme-related diseases 
discussed, ataxia is a common neurological phenotype. Purkinje cells in 
cerebellum are more sensitive to DNA damage than other neuronal cell 
types, as shown by the phenotype of ataxia, which is one of the main 
phenotypes that arises from mutant DNA repair proteins. A possible reason 
for this selective vulnerability is that Purkinje cells are large and  have large 
nuclei due to less genome-wide condensation [113]. This chromatin state 
allows the cells to be exposed to more DNA damage than neurons than in 
a condensed chromatin structure.  
 
1.8 Evidence for HRR in proliferating neuronal cells 
Previous research performed in the Langley laboratory (unpublished) shows 
that HRR repair occurs in proliferating neuronal cells (Figure 1.5). For these 
experiments, HT22 cells were used. These cells are derived from a mouse 
neuronal hippocampal cell line. The HT22 cells were stably transfected with 
a DR-GFP transgene reporter system [114], which is engineered to contain 
a full-length green fluorescent protein (GFP) gene with a 5’-premature stop 
codon/I-SceI recognition sequence. I-SceI restriction endonuclease has no 
recognition sequence in the mouse genome, so in each cell the expression 
of I-SceI would induce a single DSB in the 5’-premature stop codon/I-SceI 
recognition sequence of the GFP. The reporter vector also contained a 
portion of the wild-type GFP sequence, which and provide a template for 
HRR if it were to occur after I-SceI expression. In this case, the GFP 5’- 
premature stop codon would be removed and a functional GFP protein 





The assay showed that HRR occurred in proliferating neurons (Figure 1.5). 
This was an experiment to validate the assay and show that neuronal cells 
were capable of HRR. The next step after this project is to show that HRR 
can occur in non-proliferating neuronal cells.  
 
Figure 1.4 HRR assay, using a DR-GFP transgene reporter system, to determine if HRR occurs 
in proliferating neuronal cells. CMV is a promoter used to drive gene expression. Puromycin 















1.9 Project – Do Neurons Repair DNA Double-Strand 
Breaks by Homologous Recombination Repair? 
Neurons are terminally differentiated, non-dividing cells that accumulate 
between 10 and 50 DNA DSBs in each cell every day [41]. This is a 
considerable amount of DNA damage, and if left unrepaired it can lead to 
the formation of DNA lesions, lost genetic information, and mutagenesis, 
which can contribute to neurodegenerative pathologies [42]. Because of 
these severe consequences, it seems that a high-fidelity process to repair 
these strand breaks would be crucial.  
 
Previous research in a mouse hippocampal cell line, HT22 cells, has shown 
that HRR can occur in proliferating neuronal cells. However, following birth, 
neurons are predominantly post-mitotic, and we do not yet know if HRR can 
be achieved in non-proliferating neurons. This previous work was the first 
step in determining if neuronal cells are capable of HRR. The goal of this 
project is to use the DR-GFP transgene reporter system [114] (Figure 1.4) 
in non-proliferating neuronal cells to conclusively determine whether HRR 
is used as a DSB repair pathway in post-mitotic neurons.  
 
1.10 Aims and Objectives 
Research Objective 1:  
Differentiation protocol 
(i) Determine the best differentiation protocol for N2a cells – includes  
counting cells before and after treatment 
a. Foetal bovine serum (FBS) concentration (10% or 1%) 
b. Addition of retinoic acid (RA) or no RA 
(ii) Use protocol that shows best differentiation of N2a cells ( determined 
by cell counting) and further test its differentiation by: 
a. EdU incorporation 
b. Immunofluorescent microscopy 
 




Amplify and sequence DR-GFP transgene reporter and I-SceI 
expression plasmids. Establish a neuronal cell line that contains 
stably integrated DR-GFP in its genome  
(i) Transform DH5-alpha competent E. coli bacterial cells with DR-GFP 
transgene reporter or I-SceI expression plasmids.  Culture/expand 
transformed bacteria and purify DR-GFP or I-SceI plasmids 
(ii) Confirm plasmids by restriction endonuclease digestion mapping 
(iii) Transfect N2a cell line (ATCC CCL-131) with DR-GFP plasmid and 
select for stable genomic integration using puromycin (plasmid 
contains a puromycin resistance gene).  This will generate a stable cell 
line containing DR-GFP that can be tested under different conditions 
for HRR 
(iv) Test for integration by PCR 
 
Research Objective 3: 
Examine whether HRR occurs in proliferating neurons 
(i) N2a-DRGFP cells will be tested for HRR  
a. N2a-DRGFP cells will be transfected with I-SceI vector to induce 
DSB at the N-terminal I-SceI restriction endonuclease/stop site of 
DR-GFP  
b. GFP-immunofluorescence microscopy will be used to monitor 
neuronal DNA repair:  If repair of this site occurs through NHEJ no 
fluorescence will be observed; if repair of this site occurs through 
HRR fluorescence will be observed 
 
Research Objective 4: 
Examine whether HRR occurs in post-mitotic neurons 
(i) N2a-DRGFP cell line will be differentiated using 10μM retinoic acid / 
1% FBS.  This will generate post-mitotic neurons (which can be 





(ii)  Post-mitotic N2a neurons will be transfected with I-SceI vector to 
induce DSB at the N-terminal I-SceI restriction endonuclease/stop site 
of DR-GFP 
(iii) GFP-immunofluorescence microscopy will be used to monitor 
neuronal DNA repair: If repair of this site occurs through NHEJ no 
fluorescence will be observed; if repair of this site occurs through HRR 





2 Chapter 2 
Materials and Methods 
All methods were carried out at the University of Waikato, in either the E3.11, 
E3.13 (PC2 lab), or C.2.09. All experiments were carried out aseptically in 
areas cleaned with 70% ethanol.  
 
This chapter contains the methods that were repeatedly performed 
throughout this project. Individual experimental details are written in the 
methods section of each chapter. 
 
2.1 Common Solution Preparations  
Solutions Composition 
N2a growth media 89% DMEM media 
10% FBS 
1% Penicillin-Streptomycin 
1% FBS media 10% N2a growth media 
90% DMEM 
Retinoic acid stock solution (12.45 
mM) 
50 mg Retinoic acid 
1.5 ml DMSO 
TE (Tris-EDTA) buffer (10 μM) 5 ml 1M Tris pH 8 
1 ml 0.5M EDTA pH 8 
496 ml dH2O 
TAE buffer 50x stock  
 
100 ml 0.5M EDTA pH 8  
242 g Tris base 
57.1 ml acetic acid 
dH2O to final 1 L volume 
 
Puromycin stock solution (50 
mg/ml) 
50 mg Puromycin 
1 ml dH2O 





2.2 N2a Cells 
The N2a cells have an authority number of GMC001340. The cell line used 
is derived from Mus musculus. Transformations will take place in E. coli cells. 
The bacterial transformation and mammalian transfections of these cells 
have the HSNO number GMD101146 and will be developed under the 
Facility 759’s EPA approval APP201152_s67. 
 
The N2a cell line was obtained from the -80°C cell culture inventory in the 
C-Block laboratories of the School of Science at the University of Waikato. 
The growth media for these cells was; DMEM media (Gibco) with 10% FBS 
(Gibco) and 1% Penicillin-Streptomycin (Thermo Fisher). The cells were 
kept in the incubator in C2.09 during the cell culturing process with the 
standard conditions: 37°C, and 5% CO2, in a humidified incubator. The cells 
were passaged when they reached 80% confluency and were topped up 
with fresh media every other day to maintain their health and optimal growth. 
The cells were then moved to E3.13 (PC2 lab) once transfections began 
and stored in the same incubator conditions. 
 
2.2.1  Frozen  N2a Cells 
Before starting experiments N2a cells were thawed. Thawing of frozen N2a 
cells was done rapidly to minimise cell death. To maintain the highest 
number of cell survival, a vial of N2a cells was thawed for 2 minutes in a 
37°C water bath. Once the cells were thawed, they were centrifuged for 7 
minutes at 125 x g to form a pellet. The supernatant was removed, and the 
pellet was resuspended in growth media. The cells were then grown in a 10 
cm plate before being transferred to a 75 cm3 flask once cells had become 





2.2.2  Subculture of  Cells 
Phosphate buffered saline (PBS) (Gibco) and growth media were warmed 
to 37°C in the incubator before cells were sub-cultured,  to avoid cold shock 
to the cell when these reagents were added. 
 
N2a is an adherent cell type. To passage the cells, media was removed, 
and the cells were washed briefly with 10 ml of PBS. Once PBS was 
removed, 1 ml of 0.25% Trypsin-EDTA (Gibco) was added. Trypsin breaks 
the bonds in proteins, which allowed for the cells to be dissociated from the 
surface of the flask. The flask was then placed in the incubator for five 
minutes or until it was observed under the microscope that the cells had 
dissociated from the surface of the flask and were in the trypsin solution. To 
inactivate trypsin activity, 20 ml of media was added for a 1:2 passage (10 
ml for each new flask) – adjust accordingly for a larger/smaller passage. 10 
ml of the media was removed and added to a new flask.  
 
Transfection of cells occurred between passages 5 and 25 post-thaw.  
 
2.3 LB Agar + Ampicillin Plates 
Seven grams of LB Broth with agar (Lennox) (Sigma) was added to 200 ml 
dH2O and mixed. The bottle was autoclaved for 20 minutes at 120°C. The 
LB agar mixture was then removed from the autoclave and left to cool to 
approximately 60°C. 
 
A Bunsen burner was used to maintain a sterile working area and for flame 
sterilisation. 200 μl of 100 mg/ml ampicillin (Sigma) was added to the LB 
agar and mixed. Approximately 10 ml of the LB agar and ampicillin mixture 
was added to each petri dish. The petri dishes were left to cool for one hour, 
then stacked on top of each other and placed in the fridge (4°C) upside 





2.4 LB Growth Media 
LB growth media was prepared by adding 6.25 g of LB Broth powder (Sigma) 
to 250 ml of dH2O and mixing vigorously. The bottle was autoclaved for 20 
minutes at 120°C. LB broth was then removed from the autoclave with heat 
resistant gloves and left to cool. LB broth was stored in the fridge (4°C) when 
not in use. 
 
2.5 Agarose Gel 
Agarose gels (1 to 2%) were made by mixing 1 to 2 g of UltraPure agarose 
powder (Invitrogen) into 100 ml of 1 x TAE buffer (Thermo Fisher) and 
microwaved, mixing every 30 seconds, until all agarose particles were 
dissolved. 2 μl of 10 mg/ml ethidium bromide was then added to the gel and 
mixed. This was then poured into a 15-well gel mould and left to set at room 
temperature.  Prior to use it was submerged in 1 x TAE buffer in a DNA 





3 Chapter 3 
Differentiation of N2a Cell Line 
3.1 Introduction 
In proliferating cells, DSBs are said to occur by HRR, a high-fidelity process, 
as clonal expansion of misrepaired DNA could potentially lead to cancer. 
DSBs in post-mitotic cells, by contrast, are thought to be repaired by NHEJ, 
a low fidelity process, as it is less time- and energy-efficient, and because 
the consequences of misrepaired DNA are not as detrimental to the 
organism. 
 
For this project we are investigating what DSB repair pathway is used in 
post-mitotic neuronal cells. Neuroblastoma cells, such as N2a, are cancer 
cells, which means that they are proliferative. However, given the right cell 
culture conditions, N2a cells can be induced towards a post-mitotic, 
differentiated phenotype [115]. The aim is to utilise this important feature of 
N2a cells to best replicate a post-mitotic neuronal state that exists in vivo.  
 
The first task of this project was to determine the best post-mitotic cell 
induction method for N2a cells. In the first experiment, serum deprivation 
was used, and it was found that cells were still able to proliferate at 1% FBS 
concentration. We then tested 1% FBS concentration with retinoic acid (RA), 
which showed non-proliferative state as shown by cell counting. Once the 
optimal FBS and retinoic acid (RA) concentration was found by cell counting, 
an EdU incorporation assay was used to definitively conclude that the N2a 






3.2.1 Induction of a Non-Proliferative N2a Cell State  
N2a cells need to be post-mitotic for the HRR experiment. Different 
differentiation media compositions were investigated to determine which 
cell culture conditions would best promote a non-proliferative state in the 
N2a cells. To test different cell culture methods, 24-well plates were used.   
 
3.2.1.1 Serum Deprivation 
The first culture conditions that were piloted were DMEM with 10% serum 
versus DMEM with 1% serum. Cells were placed into 24-well plates at a 
density of 1 x 104 cells per well. Cells were first cultured in 0.5 ml of growth 
media per well and placed in the incubator for 24 hours so the cells could 
adhere to the plate and recover. 
 
After 24 hours, one well was trypsinised and the cells were counted by 
haemocytometer [116], to determine a starting cell number (10% FBS 
condition). The media was changed in each remaining well, with one of the 
two conditions; 10% FBS or 1% FBS. 
 
Cells were counted daily for 7 days per condition to establish a growth curve. 
This experiment was carried out in duplicate and results were averaged.  
 
3.2.1.2 Retinoic Acid Addition and Serum Deprivation 
The second cell culture conditions to be piloted were to employ a range of 
retinoic acid (RA) concentrations in addition to the serum deprivation (1% 
FBS media). Different concentrations of RA used were; 5 μM, and 10 μM. 
 
Cells were first seeded in 24-well plates at a density of 1 x 104 cells with 0.5 
ml of growth media. After 24 hours the media was changed to one of the 
conditions as stated in Figure 3.1. 10% FBS and 1% FBS conditions were 





Cells were cultured and observed for toxicity for 7 days. The media in the 
24-well plates was changed every 3 days so that the nutrients for the cell’s 
growth was not exhausted. Each day one well for each condition was 
trypsinised and counted by haemocytometer. The standard growth curve 
was calculated, and conditions were plotted against this to determine cell 







Figure 3.1 Conditions for 24-well plate differentiation experiment 
 
3.2.1.3 EdU Incorporation 
The EdU incorporation assay was achieved by the use of a Click-iT EdU 
Imaging Kit (Thermo Fisher) and is an adaption of the more traditional BrdU 
cell proliferation assay. EdU (5-ethynyl-2’-deoxyuridine) is a nucleoside 
analog of thymidine and is incorporated into DNA during DNA synthesis. 
EdU detection is based on click chemistry, which is a reaction between a 
picolyl azide and an alkyne. The EdU contains the alkyne and the Alexa 
Fluor dye contains the picolyl azide. The picolyl azide-Alexa Fluor dye is 
small in size, so it can readily gain access to the DNA using mild detergent 
permeabilization to detect the incorporation of EdU. An Alexa Fluor 594 (red) 
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dye was used so as to be compatible with GFP (green) and DAPI (blue) 
fluorescence in later experiments. As EdU will only be incorporated into 
DNA if the cell is proliferating, a lack of red fluorescence would be indicative 
of non-proliferating cells.   
  
Cells were seeded in 24-well plates at a density of 1 x 104 cells with 0.5 ml 
of growth media. After 24 hours the media was changed to one of the 
conditions: 10% FBS, 1% FBS, or 1% FBS containing 5 μM or 10 μM RA, 
as described in Figure 3.1.  
 
After 7 days of culture, cells were removed from the incubator. The media 
was removed from cells and the cells were washed with PBS. This was done 
to remove any cell debris and residual media. The PBS was removed and 
1.5 ml of each culture media containing 10 μM EdU was added to each well. 
Cells were then incubated for 36 hours to allow time for the EdU to 
incorporate into DNA if the cells were proliferative.  
 
After 36 hours, the media was removed from the cells and cells were 
washed with PBS.  1 ml of 3.7% formaldehyde in PBS was added to each 
well and incubated for 15 minutes. Formaldehyde is a cross-linking agent 
that fixes cells and preserves their cellular morphology. After 15 minutes, 
the formaldehyde was removed, and the cells were washed twice with 1 ml 
of 3% BSA in PBS. When the wash solution was removed, 1 ml of 0.5% 
Triton X-100 (Sigma Aldrich) in PBS, was added to each well and incubated 
at room temperature for 20 minutes. Triton X-100 was added as it 
permeabilises the cell membrane.  
 
A reaction cocktail was made containing 1X Click-iT reaction buffer (5.16 
ml), CuSO4 (240 μl), Alexa Fluor azide (14.4 μl), and reaction buffer additive 
(6 ml). Triton X-100 was removed from the cells, and cells were washed 
twice with 3% BSA in PBS. The wash solution was removed and 500 μl of 
the reaction cocktail was added to 12 of the 24 wells (Row 2, 3, and 4 were 
used; Figure 3.1). The 24-well plate was gently rocked to evenly distribute 




and was left to incubate at room temperature for 30 minutes. The reaction 
cocktail was then removed, and the cells were washed with 1 ml of 3% BSA 
in PBS.  
 
The wash solution was removed, and the cells were washed again, with 1 
ml PBS. The wash solution was removed and 1 ml of DAPI (5 μg/ml) in PBS 
was added to the wells. DAPI is a blue stain that can stain living and 
permeabilised cells. The plate was covered in tinfoil to protect it from light 
and the plate was left to incubate at room temperature for 30 minutes. The 
DAPI solution was then removed and the cells were washed twice with 1 ml 
of PBS. The PBS was then removed. 
 
The cells were then taken to the confocal room to be imaged. 
 
3.2.1.3.1 Confocal Microscopy 
Two laser channels were used; 
Channel 1 settings: 
 Dye – Alexa Fluor 594 
 Excitation wavelength – 590 nm 
 Emission wavelength – 615 nm 
Channel 2 settings: 
Dye – DAPI 
 Excitation wavelength – 358 nm 
 Emission wavelength – 461 nm 
 
Once cells had been visualised photos were taken and cells were counted. 
Three photos were taken for each condition. Blue cells with red stain and 
blue cells without red stain were counted separately. Cells that were stained 







3.3.1 Growth Curve of N2a cells 
 
 
Figure 3.2 Growth curve of N2a cells with differentiation media  
 
From the growth curve (Figure 3.2), all cells observe a lag phase for 
approximately the first three days followed by an exponential growth phase. 
After 6 days the rate of division for cells begins to decline, which is most 
likely due to the high level of confluency and cell contact inhibition.  
 
Cells in the 10% FBS condition grow the most rapidly, as to be expected as 
this is the optimal growth medium for N2a cells. Cells are still able to grow 
and divide rapidly in the serum deprivation condition of 1% FBS. The 
addition of RA shows to have slowed cell growth and division, as can be 
seen in the 1% FBS + 5 μM RA, and 1% FBS + 10 μM RA conditions, with 
the 10 μM RA condition showing the least cell growth. This data suggests 























Growth Curve of N2a cells 




3.3.2 EdU Incorporation 

























Table 3.1 EdU incorporation assay in 10x magnification for 10% FBS Condition, 1% FBS 
Condition, 1% FBS + 5 μM RA Condition,  and 1% FBS + 10 μM RA Condition. Blue cells = cells 
that have not incorporated Edu into its DNA; Red cells = cells that have incorporated EdU into 
its DNA. 
 
The incorporation of EdU into each cell condition can be seen in Table 3.1. 
DAPI is a blue fluorescent DNA stain and can visualise nuclear DNA in living 
and fixed cells. This means that all cells will be stained blue. EdU is a red 
fluorescent marker that is incorporated into proliferating DNA, so will only 
stain proliferating cells and not cells that are non-dividing. Cells that have a 
blue and red fluorescence show that the cells are alive and are proliferative. 
Cells that are only stained blue and not red show cells that are not 
proliferative. 
 
The 10% FBS condition has the greatest number of red and blue co-staining, 
followed by the 1% FBS condition. The addition of RA as seen in the 1% 
FBS + 5 μM RA and 1% FBS + 10 μM RA conditions, shows less red and 
blue co-stained cells than the 10% FBS and 1% FBS conditions. These 






















1% FBS, 5 μM RA Condition 1% FBS, 10 μM RA Condition 
 
 
Table 3.2 EdU incorporation assay at 40x magnification for 10% FBS Condition, 1% FBS 
Condition, 1% FBS, 5 μM RA Condition,  and 1% FBS, 10 μM RA Condition. Blue cells = cells 
that have not incorporated Edu into its DNA; Red cells = cells that have incorporated EdU into 
its DNA. 
 
40x magnification images of the EdU incorporation assay (Table 3.2)  were 
taken to represent the differences in the number of proliferative vs non-
proliferative cells. In the 10% and 1% FBS conditions it is clear that there is 
more proliferating cells than non-proliferating cells. In the conditions with the 
addition of RA it is clear than there are more non-proliferating cells vs 





3.3.2.1 Cell Count 
Cells from each image in Table 3.1 were counted and their results were 
tallied into Tables 3.3 – 3.6. This showed the number of proliferative cells 
vs non-proliferative cells and showed the best differentiation method for N2a 
cells. 
 
10% FBS Condition 






A 1037 337 1374 75% 25% 
B  1011 259 1270 80% 20% 
C 1030 266 1296 79% 21% 
Average 78% 22% 
Standard Deviation 2.16 
Table 3.3 Cell count for 10% FBS condition after EdU incorporation. 
 
Table 3.3 shows that in the 10% FBS condition 78% of cells are proliferative, 
and only 22% of cells are non-proliferative. Because this condition is the 




1% FBS Condition 






A 1143 373 1516 75% 25% 
B  715 418 1133 63% 37% 
C 1075 511 1586 67% 33% 
Average 68% 32% 
Standard Deviation 4.99 





Table 3.4 shows that in the 1% FBS condition 68% of cells are proliferative, 
and only 32% of cells are non-proliferative. This result shows that serum 
deprivation alone is not enough to differentiate N2a cells as the cells are still 
highly proliferative in the 1% FBS condition.  
 
Table 3.5 Cell count for 1% FBS, 5 μM RA condition after EdU incorporation. 
 
Table 3.5 shows that in the 1% FBS condition with the addition of 5 μM RA, 
45% of cells are proliferative and 55% of cells are non-proliferative. This 
result shows that serum deprivation with the addition of RA shows a higher 
percent of cell differentiation than serum deprivation alone, as more than 
half of the cells have differentiated after 7 days, whereas in the 1% FBS 
condition only one-third of cells had differentiated. However, there is still a 
significant number of cells that are able to proliferate, so a higher 
concentration of RA seems likely to best differentiate N2a cells. 
 
 
Table 3.6 Cell count for 1% FBS, 10 μM RA condition after EdU incorporation. 
1% FBS, 5 μM RA Condition 






A 735 901 1636 45% 55% 
B  954 1005 1959 49% 51% 
C 1622 2419 4014 40% 60% 
Average 45% 55% 
Standard Deviation 3.68 
1% FBS, 10 μM RA Condition 






A 367 1003 1370 27% 73% 
B  552 942 1494 37% 63% 
C 585 1126 1711 34% 66% 
Average 33% 67% 





Table 3.6 shows that in the 1% FBS condition with the addition of 10 μM of 
RA, 33% of cells are proliferative and 67% of cells are non-proliferative. This 
result shows that two-thirds of all cells are non-dividing, which is significantly 
higher than serum deprivation alone (only one-third of cells non-dividing) 
and has more non-dividing cells than the addition of 5 μM RA (roughly half 
the cells were non-dividing). Higher concentrations of RA were used in 
preliminary studies (data not shown) and was shown to be toxic, as there 
was a loss of cells. The best differentiation method for N2a cells, as shown 
by EdU incorporation and cell counting is 1% FBS with the addition of 10 
μM RA, over a period of seven days.  
 
3.3.2.2 T-Test 
Table 3.7 T-Test of 10% FBS and 1% FBS; 1% FBS, 5 μM RA; and  1% FBS, 10 μM RA.  
 
A t-test was performed to determine the statistical significance between the 
growth condition (10% FBS) and the differentiation conditions (1% FBS; 1% 
FBS + 5 μM RA; and 1% FBS + 10 μM RA) (Table 3.7). At the α=0.05 level 
there is sufficient evidence to conclude that there is a significant difference 
between the growth condition and  the 1% FBS, 5 μM RA (p=0.0072) and  
1% FBS, 10 μM RA (p=0.0010). However, at the α=0.05 level there is not 
sufficient evidence to conclude that there is a significant difference between 






10% FBS 1% FBS 1% FBS, 5 μM RA 1% FBS, 5 uM RA 
25% 25% 55% 73% 
20% 37% 51% 63% 
21% 33% 60% 66% 





Figure 3.3 The percentage of non-proliferating cells in growth and differentiation conditions, 
with error bars and p-values. 
 
Figure 3.3 summarises the percentage of cells that are non-proliferative in 
each growth and differentiation condition. This graph shows that serum 
deprivation and RA addition results in a higher percentage of non-
proliferative cells and this is statistically significant. 1% FBS and 10 μM RA 
also has higher percentage of non-proliferative cells than 1% FBS and 5 μM 
of RA which is statistically significant. 
 
The results from cell counting showed that even after 7 days in 
differentiation media the 1% FBS and 10 μM RA condition still had 
proliferative cells. This could have been due to the cell lineage fate of these 
cells. Some of the cells may have differentiated into glial cells, which can 




The objective of this chapter was to determine the optimal differentiation 







under normal incubator conditions was generated. Serum deprivation was 
initially used to differentiate N2a cells; however, it was found through cell 
counting that cells were still highly proliferative. Because of this, serum 
deprivation with the addition of RA was used. Cells were counted over the 
span of seven days and these results were plotted against the standard 
growth curve of N2a cells in growth media. The growth curve of these cells 
under different conditions showed that 1% FBS, and 10 μM RA over the 
course of seven days showed the lowest proliferation. 
 
After cell counting, an EdU incorporation assay was used to show the 
number of non-proliferative cells for each condition and definitively conclude 
if cells were not proliferating. EdU incorporation showed that the 1% FBS + 
10 μM RA condition had the highest number of cells that were non-
proliferating (67%). From this, it was established that for N2a cells the 
optimal protocol for differentiation was to treat cells with 1% FBS media and 
10 μM RA over the course of seven days. This differentiation protocol will 
be used in the HRR experiment to test if HRR occurs in non-proliferating 
neuronal cells. 
 
This chapter was important for learning the protocol for EdU staining. The 
aim of this project is to investigate whether HRR occurs in non-proliferative 
neuronal cells. Thus, in the HRR experiment, cells can be differentiated 
using 1% FBS and 10 μM RA media, as this was found to be most effective, 
and will be stained with EdU and DAPI so only cells that are non-proliferative, 
will be included. In the HRR experiment, if a cell shows green fluorescence 
and blue fluorescence, and no red fluorescence, it will confirm that HRR has 
occurred in post-mitotic neuronal cell. From this chapter, it was confirmed 
that EdU is a suitable test to show proliferative vs non-proliferative cells.  
 
A growth curve shows the phases in which a cell culture generally goes 
through. The first phase is the growth phase where the culture have a 
delayed growth due to the stress of sub-culturing and the small number of 
cells. The cells then go into an exponential or log phase, where the cells are 




stationary phase in which the cells growth reaches a plateau, usually due to 
the exhaustion of media or cell contact-inhibition because of confluency. In 
our experiment, the media was changed in the cells every three days to 
prevent the depletion of nutrients and allow the cells to grow – unless the 
media conditions caused the differentiation of the cells, which would be 
seen by a decrease in cell growth. 
 
In initial experiments for cell counting, cells were seeded at two different 
densities: 1 x 104 cells per well and 2 x 104 cells per well. It was found that 
cells seeded at 2 x 104 became overcrowded quickly and needed to be sub-
cultured, whereas cells seeded at 1 x104 cells per well did not need to be 
sub-cultured. Because of this, in all future experiments the cells were 
seeded at the density of 1 x 104 cells. One problem that was encountered 
with this density was that the 10% FBS condition cells became fully 
confluent after seven days. Because of this, all cells were washed twice with 
PBS before the EdU assay to ensure that dead or unhealthy cells were 
removed and allowed the other cells to remain healthy.  
 
Various studies have used RA and serum deprivation to differentiate cells 
[117-119]. However, different concentrations are used, requiring the need 
for multiple media compositions to be tested.  Before the 5 μM and 10 μM 
concentrations were chosen, a preliminary experiment was performed in a 
6-well plate with RA concentrations of 5 μM, 10 μM, 20 μM, and 50 μM. It 
was found that 20 μM and 50 μM RA were toxic to the N2a cells and resulted 
in a large number of cell death, which is why 5 μM and 10 μM concentrations 
were used.  
  
EdU incorporation is a cell proliferation assay that is an alternative to a BrdU 
assay. BrdU is a nucleoside that is an analog of thymidine. BrdU 
incorporation is an antibody-based reaction and requires denaturation of 
DNA to detect the incorporated nucleoside. BrdU is a time-consuming 
process and is less accurate than EdU, as artifacts may arise from the 
denaturation and antibody steps. EdU incorporation was a simple and easy 




4 Chapter 4 
DNA  Vectors and Generation of a Stable 
Cell Line 
4.1 Introduction 
To test if HRR can occur in post-mitotic neurons, DNA plasmids DR-GFP 
and I-SceI needed to be amplified and purified. Once purified, DR-GFP can 
be transfected into N2a cells and create generate a stable cell line of N2a-
DRGFP cells.  
 
The process of amplifying and purifying DNA plasmids involves bacterial 
transformation. This process utilises the concept of horizontal gene transfer. 
This is the process of genetic material being passed between bacteria by 
means other than from parent to offspring (vertical gene transfer) and is very 
rare in nature. Because of this, specialised cells that have a cell membrane 
more permeable have been engineered, which allows genetic material to 
enter the cell after heat shock. After the plasmid DNA has been transformed 
into the bacterial cell, the DNA can be purified by miniprep.  
 
The transfection of the purified DR-GFP plasmid into proliferating N2a cells 
is achieved by lipofection. Lipofection allows negatively charged DNA to 
aggregate with positively charged liposomes. Liposomes are a vesicle that 
can easily pass through the cell membrane, thus allowing the DNA to enter 
the cell. Once cells have been transfected with DR-GFP, puromycin is 
added to media as DR-GFP has a puromycin resistance gene. After 
treatment with puromycin only cells that have stable integration of DR-GFP 







4.2.1 Bacterial Transformation 
Competent E.coli cells, which have an altered cell wall that is designed to 
make cells more permeable and allow genetic material to enter the cell, are 
used for the process of bacterial transformation.  
 
One tube (500μl) of DH5α competent E. coli (Invitrogen) was removed from 
the -80°C freezer and immediately placed on ice. They were left to sit on the 
ice for 15 minutes to slowly thaw.  
 
Two plasmids stored on filter paper – I-SceI and DR-GFP – were added to 
labelled Eppendorf tubes. These two plasmids were sourced from Weil 
Cornell Medical College in New York. TE buffer (60 μl) was added to each 
tube, vortexed, then centrifuged at 16,100 rpm for 30 seconds.  
 
Another three Eppendorf tubes were labelled with the following: I-SceI, DR-
GFP, and Control. Competent cells (110 μl) were added into each of the  
samples and 5 μl of plasmid was added to the correct tube (5 μl of dH2O 
added to control). The samples were incubated on ice for 30 minutes. The 
samples were then heat shocked in the thermomixer, which was set to 42°C 
for 30 seconds. They were removed from the thermomixer and placed 
directly onto ice and cooled for 2 minutes. LB growth media (950 μl ) was 
added to each tube and placed in the shaking thermomixer, at 37°C, for an 
hour.  The samples were then centrifuged for 30 seconds at 13,000 rpm to 
form a pellet. The media was removed so that only the pellet remained, and 
it was resuspended in 200 μl of LB growth media.  
 
Four LB agar plates were removed from the fridge and kept close to the 
flame of a Bunsen burner, to keep the area sterile. After this, 100 μl of each 
sample was spread onto separate LB agar plates. LB agar plates were 
incubated in a 37°C incubator overnight. Overnight the LB agar plates 




Once removed from the incubator they were stored in the fridge until ready 
to use.  
 
Culture tubes (4 each for DR-GFP and I-SceI) were placed next to the flame 
of a Bunsen burner. 3 ml of LB growth media was added to each tube. The 
LB agar plates were removed from the fridge and placed close to the flame. 
A sterile pipette tip was used to remove a single colony from the DR-GFP 
LB agar plate. Once a colony had been removed, the pipette tip was placed 
in a DR-GFP labelled culture tube. This was repeated three more times until 
there was a single colony in each DR-GFP culture tubes. The same process 
was repeated for the I-SceI LB agar plate and culture tubes. The culture 
tubes were incubated in the shaking incubator overnight. 1.5 ml of the 
overnight cultures were added to labelled 1.6 ml Eppendorf tubes and 
centrifuged at 8000 rpm for 2 minutes to form a pellet. The remaining 
culture/tubes were stored in fridge until needed.   
 
4.2.2 Mini Prep 
Mini prep is the process of isolating plasmid DNA from bacteria and was 
achieved by the use of a GeneJET plasmid miniprep kit (Thermo Fisher). 
The solutions were made up to their specifications. 
 
Supernatants were removed from pelleted cultures and the pellets were 
resuspended in 250 μl of resuspension solution. The tubes were vortexed 
to ensure no clumps remained in the solution. 250 μl of the lysis solution 
was added to each tube and was mixed by inversion 4-5 times. Next, 350 
μl of the neutralisation solution was added to each tube and mixed by 
inversion.  
 
Lysates were centrifuged for 5 minutes at 12,000 x g so that the cell debris 
and chromosomal DNA would form a pellet. The supernatant from each 
lysate was then transferred into labelled GeneJET spin columns and 
centrifuged for 1 minute at 12,000 x g. The flow-through was discarded and 





The GeneJET spin columns were washed by the addition of 500 μl of wash 
solution and then centrifuged at 12,000 x g for 1 minute. The flow-through 
was then discarded and the column placed back on the same collection tube. 
This wash step was repeated again, and the spin column was centrifuged 
at 12,000 x g for a further minute to ensure that all residual wash solution 
was removed. 
 
The GeneJET columns were then transferred into labelled 1.5 ml Eppendorf 
tubes and 50 μl of the elution buffer was added into the spin column. These 
were then incubated at room temperature for 2 minutes before they were 
centrifuged at 12,000 x g for 2 minutes. The columns were then discarded, 
and the tubes were stored at -20°C. 
 
4.2.3 Nanodrop Readings 
After DNA plasmids had been purified, 2μl of the sample was tested on the 
Nanodrop2000 (Thermo Fisher) machine to determine the quantity and 
quality of the DNA. Absorbance at 280nm is used as an indicator of the 
purity of nucleic acid samples. A 260/280 ratio of ~ 1.8 is accepted as pure 
for DNA.  
 
4.2.4 Restriction Digest of Plasmid DNA 
Reagents Single Restriction 
Digest 
Master Mix 
DNA 2 μl - 
10x Buffer (Thermo 
Fisher) 
2 μl 17 μl 
Enzyme (HindIII)  0.95 μl 8 μl 
dH2O 15.05 μl 128 μl 
Total 20 μl 153 μl 





Restriction endonucleases are able to cut DNA at specific recognition sites 
into smaller fragments. Hindlll (Thermo Fisher) is a restriction endonuclease 
that is able to cut both I-SceI and DR-GFP DNA plasmids at known sites. 
With this information it is possible to restriction map the plasmids and 
determine if the plasmid isolated is correct by running the cleaved DNA on 
an agarose gel. 
 
Restriction digestions were carried out on eight plasmids – four for I-SceI 
and four for DR-GFP. DR-GFP sample tubes were labelled 1-4, while I-SceI 
sample tubes were labelled 5-8. A master mix was made in a 1.5 ml 
Eppendorf tube with the components stated in Table 4.1 and then aliquoted 
into the sample tubes as per the single restriction digest in Table 4.1. DNA 
was not added into the master mix as it was added once the mix had been 
aliquoted into labelled tubes. 
 
The Eppendorf tubes containing the purified plasmids were removed from 
the -20°C freezer. DR-GFP plasmids 1-4 were added to the restriction 
digestion tubes labelled 1-4 (2 μl per tube). I-SceI plasmids 1-4 were added 
to the restriction digest tubes labelled 5-8 (2 μl per tube). The tubes were 
then incubated for 2 hours at 37°C. 
 
4.2.4.1 Agarose Gel Electrophoresis 
A 1% agarose gel was made to specifications in Chapter 2.5. Gel loading 
buffer was added to each sample of I-SceI and DR-GFP. A 1 kb ladder was 
added to the first and last lane. DR-GFP and I-SceI samples were then 
added to the lanes. The gel was run at 60 V for approximately 1.5 hours – 
the dye was observed 75% down the gel. The gel was removed and taken 
for imaging.  
 
Gels were imaged by ethidium bromide fluorescence using a UV gel 
documentation system (Image Quant LAS 400). HindIII cuts DR-GFP to 
produce fragments of the following sizes: 5542 bp, 2298 bp, and 806 bp. 




948 bp. These DNA fragments can be separated and visualised a DNA gel 
and determine if the plasmids are correct. 
  
4.2.5 Transfection of N2a cells with DR-GFP 
N2a cells were transfected with DR-GFP by the process of lipofection. DNA 
is negatively charged, and it can aggregate with positively charged 
liposomes. Liposomes are a vesicle that can easily pass through the cell 
membrane, thus allowing the DNA to enter the cell. 
 
N2a cells were plated on 3 x 10 cm plates at a confluency of approximately 
60%. They were left in the incubator for 24 hours to recover and grow. The 











40 μl - - 
DNA - 31.8 μl 41.2 μl 
Serum-free 
media 
560 μl 568.2 μl 558.8 μl 
Table 4.2 Components used for transfection of DR-GFP into N2a cells 
 
DR-GFP 1 and DR-GFP 2 were removed from the -20°C freezer. DR-GFP  
samples were diluted to a concentration 14 μg/ml of DNA by dilution with 
serum-free media. 
 
Components from Table 4.2. were made to specifications. Two 
lipofectamine samples were made, with lipofectamine added to the media 
slowly and mixed to prevent aggregates from being formed. The DR-GFP 1 
sample was added slowly to a lipofectamine sample and mixed thoroughly. 




sample. These were incubated at room temperature for 5 minutes. After 
incubation, 6.8 ml of media was then added to each sample. 
 
N2a cells on 3 x 10cm plates were removed from the incubator and their 
media was removed. They were washed briefly with 5 ml PBS. 
DNA/lipofectamine/media complexes were then added to 10 cm plates. The 
final plate was a control, where 8 ml of serum-free media was added to the 
plate. N2a plates were then placed back in the incubator for 4 hours. After 
4 hours, the media was replaced with 10 ml of a growth media.  
 
4.2.6 Puromycin Selection 
Transfected N2a cells were treated with puromycin in growth media the next 
day. DR-GFP has a puromycin resistant gene, so only transfected cells 
survive. Puromycin was added to media at a concentration of 2 μg/ml for 
two weeks and one week at 3 μg/ml, to ensure that all cells contained the 




4.3.1 Nanodrop Readings 
Sample  DNA concentration 
(ng/μl) 
260/280 
I-SceI.1 223.0 1.87 
I-SceI.2 281.5 1.88 
I-SceI.3 337.4 1.89 
I-SceI.4 388.9 1.82 
DR-GFP.1 440.4 1.88 
DR-GFP.2 339.5 1.89 
DR-GFP.3 93.0 1.89 
DR-GFP.4 449.3 1.88 
pEGFP 211.0 1.88 





The nanodrop readings show that there was a high yield overall of both I-
Scel and DR-GFP plasmids (Table 4.3). DR-GFP.3 was the only plasmid 
with a low DNA yield (93 ng/μl). The purity of these plasmids was high as 
they all had a 260/280 ratio of ~ 1.8. 
 




























Figure 4.1 Restriction Digest of DR-GFP and I-SceI 
 
From Figure 4.1, lanes 2-5 (DR-GFP) have digested DNA fragment sizes of 
5542 bp, 2298 bp, and 806 bp and lanes 6-9 (I-SceI) have digested DNA 
fragment sizes of 4717 bp and 948 bp. This confirms that the plasmids 





4.3.3 Puromycin Selection  
Over the first week following transfection and puromycin selection, 
approximately 80% cell death in the DR-GFP1 and DR-GFP2 cultures and 
100% cell death in the control culture (which did not contain any plasmid 
conferring puromycin resistance) was observed. Over the following two 
weeks, cell numbers increased in the DR-GFP cultures and eventually 
required passaging. At the end of three weeks, there were three 80% 
confluent plates per plasmid. Some of these cells were frozen as a backup 




The first objective of this chapter was to extract plasmid DNA and purify it. 
This was achieved by bacterial transformation of I-Scel and DR-GFP 
plasmids, and purification by miniprep. The status of these plasmids was 
confirmed by restriction endonuclease digestion.  
 
The main objective of this chapter was to generate a stable cell line of N2a-
DRGFP cells. DR-GFP DNA was transfected into N2a cells by lipofection 
and the transfected cells were selected for by the addition of puromycin in 
the growth media for three weeks. DR-GFP has a puromycin resistance 
gene so only cells with the DR-GFP construct could survive.   
 
This chapter was very important for generating stably integrated DR-GFP in 
N2a cells. This means that the DR-GFP gene has been integrated into the 
cell’s genome. This is opposed to a transient transfection in which the DNA 
has entered the cell but is not integrated into the genome. Stable integration 
allows the cell to replicate the DR-GFP gene, and all descendants will 
express the gene. This means that a stable cell line of N2a-DRGFP cells 
can be generated.  
 
After three weeks of puromycin selection, when the cells were assumed to 




frozen. This was to ensure that we had N2a-DRGFP cells available if the 
cells that were being sub-cultured became infected. During the course of 
the project, the cells contracted a bacterial infection and were all discarded, 
to prevent other cells in the incubator becoming infected. Bacterial infections 
are very common in cell lines, due to contamination. Because of this, it was 
good practice to have stored these cells, so we were able to thaw them out 
and begin experiments again, without too much delay.   
 
Cells also began to change morphology from small circular cells with very 
small neurites, to long neurite outgrowth and less circular shape. This could 
have been due to the very low number of cells that were on the plates during 
the initial stages of puromycin selection. When N2a cells are low in 
confluency they have space for neurite outgrowth, compared to in a 
confluent plate, where there is not much space for this growth. Another 
reason could have been that the cells were in fact starting to differentiate 
naturally. As was shown in the EdU experiment (Chapter 2), even in the 10% 
FBS condition not all cells were proliferative after seven days of cell growth. 
With the HRR experiment N2a-DRGFP cells will need to be cultured with 1% 
FBS media and 10 μM RA. These cells will then be tested for by EdU 
incorporation to determine their proliferative state. Thus, if differentiation 
was occurring it would not negatively impact this experiment, and could 
potentially be an aid, as 67% of cells were differentiated with 1% FBS media 







5 Chapter 5 
HRR in Proliferating Cells 
5.1 Introduction 
As a precursor to testing HRR in post-mitotic neuronal cells, experiments in 
this chapter were carried out to validate the N2a-DRGFP cell line. 
 
The integration of the N2a-DRGFP vector can validated by PCR of the cells. 
Primers are used that are specific for the DR-GFP vector, so if the plasmid 
is correct a portion of it will be amplified and  the DNA can be visualised on 
agarose gel. This will confirm that the construct isolated is correct and 
integration has been achieved.  
 
The validation of I-SceI can be shown by transfection into a stable cell line 
of proliferating N2a-DRGFP cells. Previous work with HT22 cells has shown 
that HRR can occur in proliferating neuronal cells. Because of this, I-SceI 
transfection in proliferating N2a-DRGFP cells should induce a single DSB 
at the I-SceI/Stop recognition site, and successful conversion to a functional 
GFP sequence could occur. 
 
Once validation of the cell line N2a-DRGFP has occurred, these cells can 









5.2.1 Transfection of I-SceI into Stable Cell Line 
N2a-DRGFP cells were seeded on a 6-well plate with 2 ml of growth media 
– three wells consisted of DR-GFP1 and three wells consisted of DR-GFP2 
(Figure 5.1). Cells were seeded at a confluency of approximately 60% and 
were left for 24 hours. After 24 hours the confluency was approximately 80%. 
 
Three conditions were used: negative control (no DNA added), GFP positive 
control (pEGFP plasmid added), and I-SceI (I-SceI plasmid added). 
Nanodrop reading of pEGFP was done using methods as stated in Chapter 
4.2.3 and results from this are included in Chapter 4.3.1. 
 
I-SceI1 and pEGFP were removed from the -20°C freezer. Samples were 
diluted to a concentration 4.7 μg/ml of DNA by dilution with serum-free 
media. 
 
The components of each sample is listed below in Table 5.1. There were 
three lipofectamine samples made in total. Lipofectamine was added to the 
media slowly and mixed to prevent aggregates from being formed. The DNA 
samples were added slowly to lipofectamine samples and mixed thoroughly. 










Lipofectamine 13.5 μl - - - 
DNA - 21 μl 22 μl - 
Serum-free media 200 μl 200 μl 200 μl 200 μl 
Table 5.1 Transfection of N2a-DRGFP  with I-SceI, lipofectamine and control samples. 
 
N2a-DRGFP Cells were washed with PBS. Once PBS was removed 200 μl 
of DNA/lipofectamine/media solution was added to each well to the 
specifications in Figure 5.1. An additional 1.3 ml of serum free media was 










1 2 3 
4 5 6 
Figure 5.1 6-well plate conditions for transfection of I-SceI and controls into DR-GFP cells 
 
After four hours the media was removed from the cells and growth media 
was added at 2 ml per well. The cells were then placed back in the incubator. 
 
After 48 hours cells were checked for fluorescence, by confocal microscopy. 
 
5.2.2 Co-Transfection of I-SceI and DR-GFP  
Co-transfection is the simultaneous transfection of two DNA plasmids. I-
SceI1 and DR-GFP1 were co-transfected into N2a cells.  
 
N2a cells were seeded on a 6- well plate with 2 ml of media. They were 
seeded at a confluency of approximately 60% and were left for 24 hours. 
After 24 hours the confluency was approximately 80%. 
 
Three conditions were used – control (no DNA added), GFP positive 
(pEGFP plasmid added), and I-SceI + DR-GFP (I-SceI1 and DR-GFP1 
plasmids added).  
 
I-SceI1, DR-GFP1 and pEGFP were removed from the -20°C freezer. The 
pEGFP sample was diluted to a concentration 5 μg/ml of DNA by dilution 




with serum-free media. I-SceI and DR-GFP were diluted to a concentration 
of 2.5 μg/ml of DNA by dilution with serum-free media. 
 
The components of each sample is listed below in Table 5.2. There were 
three lipofectamine samples made in total. Lipofectamine was added to the 
media slowly and mixed to prevent aggregates from being formed. The DNA 
samples were then added slowly to lipofectamine samples and mixed 
thoroughly. These samples were left to incubate for 5 minutes. 
 
Table 5.2 Components for co-transfection of I-SceI and DR-GFP into N2a cells 
 
Cells were washed with PBS. Once PBS was removed the DNA/ 
lipofectamine/media solution was added to wells at 200 μl per well as per 
specifications in Figure 5.2. An additional 1.3 ml of serum free media was 
added to each well the cells were placed in the incubator for four hours. 
 
After four hours the media was removed from the cells and growth media 
was added at 2 ml per well. The cells were then placed back in the incubator. 
 












Lipofectamine 13.5 μl - - - 
DNA - 11.2 μl I-SceI 
5.7 μl DR-GFP1 
22 μl - 






Figure 5.2 6-well plate of N2a cells and co-transfection components with controls. 
 
 
5.2.3 Confocal Microscopy 
The transfection and co-transfection used the same settings on the confocal 
microscope. After the appropriate incubation time, the 6-well plates were 
removed from the incubator and taken to the confocal room. 
 
One laser channel was used; 
Channel 1 settings: 
 Dye – EGFP 
 Voltage – 536 V 
 Excitation wavelength – 488 nm 
 Emission wavelength – 509 nm  
 
5.2.4 DNA Extraction 
DNA was extracted from N2a-DRGFP cells using the Chelex method [120] 
to determine its DR-GFP status. The cells were first trypsinised. After cells 
had dislodged from the flask, 5ml growth media was added, and cells were 
centrifuged in a falcon tube at 500 x g for 5 minutes. The supernatant was 
then removed, and the pellet was resuspended in 500 μl of 5% PBS. This 
1 2 3 
4 5 6 




was then transferred into an Eppendorf tube and centrifuged at 500 x g for 
a further 5 minutes. PBS was removed and 500 μl of 5% Chelex 100 (Bio-
Rad) in sterile dH2O was added to the Eppendorf tube. The tube was heated 
to 99°C for 10 minutes in the thermomixer. Once removed it was centrifuged 
for 5 minutes at 500 x g. The supernatant was then transferred to another 
Eppendorf tube and the pellet discarded.  
 
5.2.5 Polymerase Chain Reaction  
The N2a-DRGFP status of the cells was determined by polymerase chain 
reaction (PCR) and was visualised on an agarose gel. Two sets of primers 
were used: EGFP-C / PuroF and pCAG-F / EGFP-C-R. These two sets of 
primers both amplify the forward and reverse of the DR-GFP insert. EGFP-
C/PuroF amplifies 1074 bp and pCAG-F/EGFP-C-R amplifies 1033 bp. The 














Figure 5.3 Plasmid map of pDRGFP and the primers used for PCR to determine N2a-DRGFP 







Reaction Components Single PCR Reaction Master Mix (x2) 
10x PCR Buffer 2.5 μl 10 μl 
Primer 1 0.5 μl 2 μl 
Primer 2 0.5 μl 2 μl 
DNA  5 μl - 
MgCl 2 μl  8 μl 
dNTPs 2.5 μl 10 μl 
H20 11.75 μl 47 μl 
Taq Polymerase 0.25 μl 1 μl 
Table 5.3 Components for PCR to determine N2a-DRGFP status of cells. 
 
Two separate master mixes were made up to the specifications in Table 5.3. 
The first master mix contained the primers EGFP-C / PuroF and the second 
master mix contained the primers pCAG-F / EGFP-C-R. These primers 
were all used at a working concentration of 30 pmol/μl. From the master 
mixes, 20 μl was added into PCR tubes (4 tubes per master mix). DNA was 
then added to each tube according to the specifications in Table 5.4. 
 
Conditions for PCR – DNA and primers used for each sample 
1. No DNA / EGFP-C / PuroF 
2. DR-GFP1 / EGFP-C / PuroF 
3. DR-GFP2 / EGFP-C / PuroF 
4. Plasmid DNA / EGFP-C / PuroF  
5. No DNA / pCAG-F / EGFP-C-R 
6. DR-GFP1 / pCAG-F / EGFP-C-R 
7. DR-GFP2 / pCAG-F / EGFP-C-R 
8. Plasmid DNA / pCAG-F / EGFP-C-R 












EGFP-C CATGGTCCTGCTGGAGTTCGTG 61 22 
PuroF GCAACCTCCCCTTCTACGAGC 60 21 
pCAG-F GCAACGTGCTGGTTATTGTG 57 20 
EGFP-
C-R 
CACGAACTCCAGCAGGACCATG 60 22 
Table 5.5 Primers used for PCR to determine N2a-DRGFP status of cells. 
 
The PCR conditions were as follows:  
 
1. 94°C for 3 mins for initial denaturing of the DNA, and to activate the 
Taq DNA polymerase (Invitrogen)   
2. 35 cycles of:  
a. 94°C for 30 secs (Denaturing) 
b. 62°C for 30 secs (Annealing) 
c. 72°C for 30 secs (Elongation) 
d. Final elongation at 72°C for 2 mins 
3. Hold at 4°C indefinitely 
 
The resulting product was then analysed by agarose gel electrophoresis.  
 
5.2.5.1  Agarose Gel Electrophoresis 
A 1% agarose gel was made as per specifications in Chapter 2.5. Gel 
loading buffer was added to each sample. A 5 kb ladder was added to the 
first lane. The samples were then added to the lanes. The gel was run at 70 
V for 1 hour.   
 
Gels were imaged by ethidium bromide fluorescence using a UV gel 
documentation system (Image Quant LAS 400). The PCR amplification 
product from the EGFP-C / PuroF primer combination would be expected to 




C-R primer combination would be expected to be 1033 bp. These DNA 
amplifications can be seen on a gel and determine if the products were 
correct.  
 
5.2.6 Sequencing of Plasmid DNA 
Plasmids DR-GFP1, DR-GFP2, I-Scel1, and I-Scel2 were sent to the 
University of Waikato Sequencing Facility for sequencing. The plasmids 
were diluted with dH2O to a final concentration of 150 ng/μl. The primers 
used are stated in Table 5.6 and Table 5.7. These primers were given at a 
concentration of 5 pmol/μl.  
 
 
Table 5.6 Primers for I-SceI 
 







I-SceI Primers  
Primer 
Name 




pCAG-F GCAACGTGCTGGTTATTGTG 57 20 
Bglob-pA-R TTTTGGCAGAGGGAAAAAGA 61 20 
pDR-GFP Primers  
Primer 
Name 




pCAG-F GCAACGTGCTGGTTATTGTG 57 20 

















Figure 5.4 pDRGFP vector map with primers pCAG-F and EGFP-C-R highlighted 
 
The pDR-GFP primers, pCAG-F and EGFP-C-R amplified a section of the 
DNA that contained the I-Scel recognition site (Figure 5.4). The EGFP-C-R 
primer is a reverse primer and pCAG-F is a forward primer. In Figure 5.4 




















The I-SceI primers, pCAG-F and Bglob-pA-R amplified a section of the DNA 
that contained that contains the ORF (Figure 5.5). pCAG-F is the forward 
primer and Bglob-pA-R is the reverse primer. 
 
Once the results from sequencing were received, they were analysed on 
Geneious Prime. All electropherograms of sequences were captured and 
analysed. The reverse primer sequences were reverse complemented. 
After each sequence was analysed, they were mapped to the plasmid 
references (Figures 5.4 and 5.5) to determine if the sequences were correct.  
 
The sequences were also put through BLAST software, using BLASTn to 






5.3.1 Transfection of I-SceI into Stable Cell Line 










Transfection of DR-GFP and I-SceI into N2a cells 
B C 















Transfection of I-SceI into N2a-DRGFP cells did not show any fluorescence 
(Table 5.8, Image B and C). Transfection of I-SceI has been shown to occur, 
as the control plasmid pEGFP was successfully transfected into N2a-
DRGFP cells, as shown by green fluorescence (Table 5.8, Image D). The 
control of no DNA did not show any fluorescence (Table 5.8, Image A), 
which shows there was no contamination and that no spontaneous GFP 
conversion had occurred in the N2a-DRGFP cells. 
 
There are three different reasons why N2a-DRGFP cells may not have 
shown fluorescence and these are: that HRR does not occur in proliferating 
N2a neuronal cells; that the I-SceI plasmid is not functional; or cells have 





5.3.2 Co-Transfection of I-SceI and DR-GFP into N2a cells 



































Co-transfection of I-SceI and DR-GFP into N2a cells did not show any 
fluorescence (Table 5.9, Image B). Transfection of I-SceI and DR-GFP has 
been shown to occur, as the control plasmid pEGFP was successfully 
transfected into N2a cells, as shown by green fluorescence (Table 5.9, 
Image C). The control of no DNA did not show any fluorescence (Table 5.9, 
Image A), which shows there was no contamination.  
 
There are three different reasons why N2a cells may not have shown 
fluorescence and these are: that HRR does not occur in proliferating N2a 
neuronal cells; that the I-SceI plasmid is not functional; or the DR-GFP 
plasmid is not correct. 
 
5.3.3 Sequencing of I-SceI  
Figure 5.6 Electropherogram of I-SceI1. Primer pCAG-F 
 
Figure 5.6 shows the electropherogram of I-Scel1 sequence from the primer 
pCAG-F. This sequence lacks distinct, single lined peaks in most areas 
which shows that the sequence is not of high quality. The data shows 
overlapping, jagged peaks, which means that the base calls that have been 





Figure 5.7 Electropherogram of I-SceI1. Primer Bglob-pA-R. Sequence has been reverse 
complemented 
 
Figure 5.7 shows the electropherogram of I-Scel1 sequence from the primer 
Blgob-pA-R. This sequence has more distinct and singled lined peaks and 
less contamination and artifacts than the electropherogram of I-Scel1 with 
the pCAG-F primer. This means that this sequence is of better quality than 
the pCAG-F primer. Data at the start and end of the sequence is of low 




Figure 5.8 Electropherogram of I-SceI2. Primer pCAG-F. 
 
Figure 5.8 shows the electropherogram of I-Scel2 sequence from the primer 
pCAG-F. This sequence lacks distinct, single lined peaks in most areas, 
which shows that the sequence is not of high quality. The data shows 




given to this sequence from the software are no longer reliable. 
 
 
Figure 5.9 Electropherogram of I-SceI2. Primer Bglob-pA-R. Sequence was reverse 
complemented. 
 
Figure 5.9 shows the electropherogram of I-Scel2 sequence from the primer 
Blgob-pA-R. This sequence has more distinct and singled lined peaks and 
less contamination and artifacts than the electropherogram of I-Scel2 with 
the pCAG-F primer. This means that this sequence is of better quality than 
the pCAG-F primer. Data at the start and end of the sequence is of low 
quality, which is to be expected. 
 
5.3.3.1 I-SceI Mapped to pCBASceI  
 
Figure 5.10 I-SceI1 sequence from pCAG-F primer mapped to pCBAScel plasmid 
 
Figure 5.10 shows that the I-SceI1 sequence from the PCAG-F primer was 
able to be mapped to the reference sequence pCBASceI. The I-SceI1 




reference sequence. This shows that the I-Scel1 sequence that we have is 




Figure 5.11 I-SceI1 sequence from Bglob-pA-R primer mapped to pCBASceI plasmid 
 
Figure 5.11 shows that the I-SceI1 sequence from the Bglob-pA-R primer, 
which has been reverse complemented, was able to be mapped to the 
reference sequence pCBASceI. The I-SceI1 sequence runs from 
approximately 2400 bp to 2700 bp on the pCBASceI reference sequence. 
This shows that the I-Scel1 sequence that we have is correct as the Bglob-




Figure 5.12 I-Scel2 sequence from Bglob-pA-R primer mapped to pCBAScel plasmid 
 
Figure 5.12 shows that the I-SceI2 sequence from the Bglob-pA-R primer, 
which has been reverse complemented, was able to be mapped to the 
reference sequence pCBASceI. The I-SceI1 sequence runs from 
approximately 2400 bp to 2700 bp on the pCBASceI reference sequence. 
This shows that the I-Scel1 sequence that we have is correct as the Bglob-
pA-R primer binds to I-SceI at 2687-2706 bp.  
 
 
The I-Scel2 sequence from the primer pCAG-F was not able to be mapped 
to the reference sequence. This could have been due to the poor quality of 
DNA reads that were obtained. Overall, the pCAG-F primed sequences 





5.3.4 Sequencing of DR-GFP 
Figure 5.13 Electropherogram of DR-GFP1. Primer EGFP-C-R. 
 
Figure 5.13 shows the electropherogram of DR-GFP1 sequence from the 
primer EGFP-C-R. This sequence lacks distinct, single lined peaks in most 
areas which shows that the sequence is not of high quality. The data shows 
overlapping, jagged peaks, which means that the base calls that have been 
given to this sequence from the software is no longer reliable.  
 
 
There was no sequence read for DR-GFP1 with the primer pCAG-F. 
 
Figure 5.14 Electropherogram of DR-GFP2. Primer pCAG-F. 
 
Figure 5.14 shows the electropherogram of DR-GFP2 sequence from the 
primer pCAG-F. This sequence lacks distinct, single lined peaks in most 
areas which shows that the sequence is not of high quality. The data shows 
overlapping, jagged peaks, which means that the base calls that have been 
given to this sequence from the software is no longer reliable. There is also 








Figure 5.15 Electropherogram of DR-GFP2. Primer EGFP-C-R. 
 
Figure 5.15 shows the electropherogram of DR-GFP2 sequence from the 
primer EGFP-C-R. This sequence lacks distinct, single lined peaks in most 
areas which shows that the sequence is not of high quality. The data shows 
overlapping, jagged peaks, which means that the base calls that have been 
given to this sequence from the software is no longer reliable.  
 
DR-GFP1 and DR-GFP2 were not able to be mapped to the reference 




























Figure 5.16 1% Agarose gel. PCR products of N2a-DRGFP cells with EGFP-C-R and pCAG-F 
primers. Controls used are no Plasmid DNA and DR-GFP plasmid. 
 
From Figure 5.16, it can be seen that DR-GFP1 and DR-GFP2 (lane 4 and 
5) have not been amplified. The no DNA control (lane 3), which was a 
negative control has not been amplified, which shows that there is no 
contamination. The DR-GFP plasmid (lane 6), which is a positive control 
has not been amplified. Amplification of pCAG-F/EGFP-C-R should have 
been 1074 bp. This PCR shows that N2a cells had not been stably 




plasmid that has been isolated may not be correct. Because N2a had not 
been stably integrated with DR-GFP, it offers an explanation on why the 
























Figure 5.17 1% Agarose gel. PCR products of N2a-DRGFP cells with Puro-F and primers. 
Controls used are no Plasmid DNA and DR-GFP plasmid. 
 
From Figure 5.17, it can be seen that DR-GFP1 and DR-GFP2 (lane 3 and 
4) have not been amplified. The no DNA control (lane 2), which was a 
negative control has not been amplified, which shows that there is no 
contamination. The DR-GFP plasmid (lane 5), which is a positive control 




1033 bp. This PCR shows that N2a cells had not been stably integrated with 
DR-GFP1 or DR-GFP2. It also suggests that the DR-GFP plasmid that has 
been isolated may not be correct.  
 
The PCR reactions show that N2a had not been stably integrated with DR-
GFP. Because this integration did not occur, it offers an explanation on why 
the transfection of N2a-DRGFP cells with I-SceI did not work. The plasmid 
DNA used as a positive control was not amplified either, which suggests 




The objective of this chapter was to validate the N2a-DRGFP cell line, 
through validation of the integration of the DR-GFP construct into N2a cells 
and also through the validation of I-SceI to cause a DSB at the I-SceI/Stop 
recognition site and successful conversion to a functional GFP coding 
sequence. It was expected that because previous work with HT22-pDRGFP 
cells showed HRR, that this experiment would too. However, the results 
from the HRR assay in proliferating N2a-DRGFP cells did not show any 
green fluorescence.  
 
There are many possible reasons behind this experiment being 
unsuccessful, the first being that HRR does not occur in neuronal cells. 
However, as these cells were still proliferating, and we have previous data 
showing that HRR can in fact occur in dividing HT22-pDRGFP neuronal 
cells, this does not seem likely.  
 
The storage of these cells could have also affected the results. The storage 
conditions of these cells are supposed to be in liquid nitrogen vapor phase 
– however, the best storage possible at our facility is a -80°C freezer. This 
storage could have led to a lower viability of cells, which meant that the cells 





The passage number could have affected this experiment. These cells were 
gifted to us from Dr Greg Jacobson, who had received them ten years prior. 
They were kept at -80°C for those ten years, before being thawed in 
February 2019. The passage number was not known to him when they were 
received, so it could be extremely high by the time we got to the HRR 
experiment. Studies show [121-126], that the passage number can affect 
the cellular productivity, protein yields, morphology, transfection efficiency, 
and growth rates of cells. However, because the pEGFP control was able 
to be transfected into cells, it seems unlikely that this is the reason why the 
experiment was unsuccessful. New cells were also thawed out and the co-
transfection was repeated, and results were still negative. 
 
Another possibility is that N2a cells are deficient for HRR. Because N2a 
cells are a neuroblastoma cell line, it could be a possibility that it is deficient 
for some repair processes. From searching literature, there was one paper 
that showed that transgene knock-in in N2a cells was achieved thorough 
homology-mediated end joining (HMEJ) and HRR [127]. This evidence 
suggests that the HRR pathway is not defective in N2a cells. 
 
Another possibility is that I-Scel was not transfected or the plasmid was 
incorrect. In the transfection experiments the pEGFP plasmid was used as 
a control to confirm that the plasmids were transfected into the N2a cells. I-
SceI was also sent away for sequencing and the results from sequencing 
showed that the plasmid was correct, as the sequences could be mapped 
to the reference plasmid. 
 
The next possibility is that the N2a cells were not stably transfected with 
DR-GFP. PCR of the N2a-DRGFP cell lines can show if DR-GFP has been 
integrated into N2a cells. The primers that were ordered for PCR to 
determine N2a-DRGFP status took a long time to be delivered. Because of 
this, after puromycin treatment, we started further experiments before 
determining whether DR-GFP had been stably integrated into N2a cells. We 




cells that did not contain a puromycin resistance gene would die and we 
would only be left with N2a cells that contained the DR-GFP construct.   
 
After the unsuccessful experiments in which I-SceI was transiently 
transfected into N2a-DRGFP cells, co-transfection of I-SceI and DR-GFP 
was attempted. In the case that integration was not achieved, this approach 
removed the need for the stable genomic integration of DR-GFP in the N2a 
cell lines. The pEGFP plasmid, which was a positive control, was 
transfected into cells and was shown by green fluorescence. The co-
transfection of I-SceI and DR-GFP did not show any fluorescence. This 
supports the idea that the DR-GFP plasmid might not be correct.   
 
When the primers arrived, a PCR of N2a-DRGFP cells was performed to 
determine whether DR-GFP was indeed in the N2a cells. This PCR did not 
show any amplification of the DR-GFP-targeted sequence, which suggests 
that cells were not stably integrated with DR-GFP. There was also no 
observed amplification of the DR-GFP plasmid, which was used as a 
positive control, which this suggests that the DR-GFP plasmid may not have 
been isolated.  
 
If the cells did not contain the DR-GFP plasmid, why did the restriction 
endonuclease map show DNA with the same cut sizes as DR-GFP? 
Moreover, how were they selected for in puromycin selection? To answer 
this question, the purified DR-GFP1 and DR-GFP2 plasmids were sent for 
sequencing.  The results from sequencing showed that the plasmids were 
not DR-GFP as the obtained sequence could not be mapped to the 
reference DR-GFP plasmid sequence. In fact, we were not able to find any 
BLAST hits for the plasmid. However, both the DR-GFP1 and DR-GFP2, 
obtained from two independent transformed bacterial colonies, were 
identical in sequence. It is also probable that the plasmid we isolated had a 
puromycin resistant gene, as it provided resistance to puromycin during N2a 





Overall, the result is very surprising as we had selected four independent 
colonies and all four had the same restriction endonuclease fragment 
pattern, which were consistent with the fragment sizes expected from a 
HindIII digestion of DR-GFP. In hindsight sequencing should have been 
done at the same time as the restriction endonuclease digestion; however, 
because the result was positive, and the primers for sequencing had not 
arrived at that time, we decided to move on with experiments. The plasmid 
had been sourced from New York and it seems likely that the lab who had 
sent us the plasmid did not send the correct one, through possible 
mislabelling or human error.   
 
Because the results we yielded from this project were negative, the next 
step would be to first obtain the correct DR-GFP plasmid; which is available 
through Addgene. After this, a stable cell line of N2a-DRGFP cells could be 
generated using the same protocol already established (Chapter 4). The 
differentiation protocol for this experiment has also been established 
(Chapter 3), in which a non-proliferative state can be achieved in the 
majority of N2a-DRGFP cells by 1% FBS media and 10 μM RA over the 
course of seven days, changing the media every three days. Once a non-
proliferative state is achieved, the cells could be transiently transfected with 
I-SceI using the established protocol (Chapter 5.2.1).  EdU incorporation 
and DAPI staining protocol (Chapter 3.2.1.3) would be used in combination 
to show that cells are non-proliferative and cell viability.  The cells could then 
be viewed by confocal microscopy to determine if HRR in post-mitotic 
neuronal cells occurs – this would be shown by green fluorescence in a blue 
stained cell. The lack of red fluorescence would show that the cell is non-





6 Chapter 6 
Final Discussion 
 
It is believed that when post-mitotic neurons are subjected to a DNA DSB, 
the repair pathway used will be the NHEJ pathway [7, 11, 18]. This pathway 
is highly inaccurate and can lead to the loss of very important information 
and accumulation of DNA lesions [11, 36]. Neurons are subjected to large 
amounts of DNA damage in every cell, each day, due to its high metabolic 
activity [41]. Neurons cannot replace themselves if they are lost, so it seems 
critical that a high-fidelity repair process, such as HRR, should be used to 
protect the integrity of these cells, as they must last a lifetime. The goal of 
this project was to determine whether HRR, a highly accurate repair process 
for DSBs, occurs in post-mitotic neuronal cells. The neuroblastoma cell line 
N2a was used to determine if HRR occurs in post-mitotic neuronal cells. 
The results did not show that HRR occurred in neurons. 
 
From this project, a differentiation protocol was established. A post-mitotic 
state can be induced in N2a cells by treatment with 1% FBS media and 10 
μM RA over the course of seven days. The lack of cell division and DNA 
synthesis in cells was determined by cell count and EdU incorporation.  
 
Next, DR-GFP and I-SceI plasmids were purified by miniprep techniques 
and concentrations were determined by nanodrop. The status of plasmids 
was determined by restriction endonuclease digestion. DR-GFP1 and DR-
GFP2 were transfected into proliferating N2a cells to produce N2a-
DRGFP.1 and N2a-DRGFP.2, respectively, and puromycin selection was 
used to obtain stably integrated lines. Once the N2a-DRGFP cell line was 
established, the cells were transfected with I-SceI to create a single DSB in 
the I-SceI/Stop recognition site in the DR-GFP vector. If HRR was to occur 
the homologous sequence on the vector would be used and the non-
functional GFP protein would be repaired and green fluorescence would be 




fluorescence. A PCR of N2a-DRGFP cells showed that DRGFP was not 
stably integrated into N2a cells. 
 
Co-transfections of I-SceI and DR-GFP into N2a cells also did not show any 
fluorescence. This suggested that the plasmids that were purified may not 
have been correct.  
 
Sequencing of I-SceI showed that the plasmid was correct. However, 
sequencing of DR-GFP showed that we did not have the correct plasmid. 
Because the plasmid was found to be incorrect, no further experiments 
could be carried out until the correct plasmid is obtained.  
 
6.1 Future Directions 
Because the DR-GFP plasmid was incorrect the next step would be to 
obtain the correct DR-GFP plasmid and use the protocol that we have 
established from this project to produce a stable cell line of N2a-DRGFP 
cells that can be differentiated and tested for HRR repair. Unfortunately, due 
to time constraints it was not possible to obtain the DR-GFP plasmid. 
However, because HRR of DR-GFP following I-SceI cleavage has been 
shown in proliferating neuronal HT22 cells, it is hypothesised that the N2a 
cell line will yield similar results.  
 
Moving forward, if HRR is shown to be successful in non-proliferative N2a-
DRGFP cells, there are further experiments that can be done to add to the 
evidence that HRR occurs in post-mitotic neurons, such as use of other cells 
lines. 
 
6.1.1 Cell Lines 
Because N2a cells are an immortalised neuroblastoma cell line, the 
experimental results from using these cells may not always represent what 
happens in vivo. However, there are advantages of using a cell line which 
include: that they are relatively easy to culture; they give rise to almost an 




cells in particular, one of the biggest positives is that they are able to be 
differentiated. While we did not confirm a differentiated neuronal phenotype 
using neural-specific antibody markers, our EdU incorporation experiments 
showed we could induce a non-proliferative state in the majority of cells. 
These results suggest the N2a cell line will be a good cell line to use once 
the correct DR-GFP plasmid is obtained. 
 
Cell lines are used before in vivo or ex vivo experiments to test hypotheses 
and show they have merit. However, cell lines can have drastically different 
physiological features from the primary cell type in which they were derived, 
and manipulations may have occurred to obtain a neuronal phenotype due 
to the addition of certain growth factors [128].  
 
The use of a primary culture is another option moving forward. Primary 
cultures are much more reliable as they are not derived from tumours or 
transformed cells, and as such, they better reflect what occurs in vivo. 
However, there are also disadvantages of using primary cultures, such as 
they are much more difficult to culture, only a small quantity of cells can be 
grown, and the transfection efficiency is greatly reduced compared to that 
of cell lines  [128]. It should also be noted that the use of primary cultures 
requires ethics approval which can take some time to obtain. The use of a 
primary culture would be the next step after showing that HRR can occur in 
non-proliferative N2a cells. 
 
To obtain primary neuronal cultures, it would be crucial to engineer mice 
that contain the DR-GFP vector in their DNA. These cells could then be 
harvested and transfection with I-SceI could occur. By using a primary 
neuronal cell culture, it would be possible to definitively establish whether 
HRR occurs in post-mitotic cells after a DSB. 
 
6.2 Possible Mechanism for HRR in Post-Mitotic Cells  
It has been long believed that HRR can only occur in the G2/M and S phase 




sequence for repair. However, there has recently been an influx of 
publications [18, 129-132] that show that RNA templates could be used as 
a homologous sequence for HRR. This evidence could provide a 
mechanism in which post-mitotic neuronal cells are able to use HRR to 
repair DSBs. 
 
HRR has typically be known to occur between two homologous DNA 
sequences; however, HRR can occur in RNA sequences, as has been 
shown through RNA viruses [129]. Research has also shown that synthetic 
RNA oligonucleotides (oligos) are able to template DSB repair in yeast and 
human cells [130, 131]. More recently, endogenous transcript RNA has 
been implicated as a possible template for HRR in yeast Saccharomyces 
cerevisiae [132]. 
 
This would mean that cells do not necessarily need to be in a certain phase 
of the cell cycle to repair DNA DSBs by HRR. Neurons are in the G0 or G1 
phase of the cell cycle as they are post-mitotic. However, they are extremely 
active cells which accumulate up to 50 DSBs in each cell, every day [41]. 
Because of this large amount of DNA damage that occurs, and the fact that 
neurons need to last a lifetime, this evidence of RNA templated DNA DSB 
repair by HRR could be the mechanism in which neurons repair their DNA 
to a high fidelity. This repair could prevent insertions, deletions, and 
translocations of extremely important coding information [11, 36]. DNA 
lesions would also be less likely to accumulate with such an accurate repair 
process.  
 
This evidence supports our hypothesis that HRR can occur in post-mitotic 
neuronal cells.  
 
6.3 HDAC Inhibition 
There is a large body of evidence that shows that a defective or ineffective 




neurodegenerative pathologies. Because of this, it seems crucial that a 
high-fidelity repair pathway is used.  
 
If HRR occurs in non-proliferative neuronal cells, it might be possible to 
enhance the HRR response by the use of HDAC inhibitors. HDAC inhibition 
is an approach that is an active area of research in the amelioration of 
neurodegenerative diseases. This is achieved by targeting HDAC activity 
via small molecule inhibitors, which allows DNA marks to be accessible for 
DNA repair factors to bind and repair DNA. This approach, however, can 
often be toxic and can lead to instability of the genome.   
 
The role of H4K16 is extremely important in the DSBR. The acetylation of 
H4K16 is linked to the HRR pathway. A possible therapeutic for 
neurodegeneration, could be to increase the acetylation of H4K16 by the 
inhibition of HDAC activity. There are a number of HDACs that have been 
targeted to deplete their acetylation activity and a few of these include; 
HDAC1, HDAC2, HDAC3, and HDAC6 [8, 51, 133-137]. 
 
After a DSB, HDAC1 and HDAC2 are rapidly recruited to DNA damage sites 
where they deacetylase H4K16 [8, 51]. The depletion of HDAC1 and 
HDAC2 have both been found to increase the levels of acetylated H4K16 
[45, 51]. HDAC2 depletion has been shown to enhance memory, increase 
the number of synapses in the brain and does not affect the DNA damage 
response negatively [133]. However, the depletion of HDAC1 is associated 
with aberrant cell cycle activity and the accumulation of DSBs, so is too toxic 
for a beneficial treatment [134].  
 
There is cell-selective toxicity in HDAC3 inhibition, where it is found to be 
toxic in mouse embryonic fibroblast cells but not overtly toxic in neurons 
[135, 136]. HDAC3 deficiency has been found to be neuroprotective towards 
low-potassium induced cell death and oxidative damage that occurs [135].  
 
HDAC6 depletion has been found to rescue neurons from cell death and 




potentially be used as a therapeutic towards neurodegenerative diseases 
that occur in the CNS [137].  
 
The use of a HDAC inhibitors has been shown to increase the HRR 
response, rescue cells from cell death, and promote their regeneration. A 
possible next step, after establishing if HRR can occur in N2a cells, could 
be to use a HDAC inhibitor in combination with I-SceI cleavage. This could 
increase the acetylation of H4K16 and the HRR pathway could potentially 
be amplified.  
 
6.4 Other Post-Mitotic Cells 
Cardiomyocytes are cells in the heart which, like neurons, are post-mitotic 
and not readily replaced if lost. It is believed that these cells also utilise the 
NHEJ pathway as the HRR pathway is limited to the S and G2 phase of the 
cell cycle [138]. However, as there is now evidence of RNA templated repair 
it could be possible that these cells repair themselves by HRR. There is also 
evidence that cardiomyocytes can be regenerated, at an extremely slow 
rate [138], which shows that these cells are capable of re-entering the cell 
cycle and means that HRR could also occur by this means.  
 
In future experiments with N2a cells, if successful, it could provide evidence 
that HRR can occur in post-mitotic cells. This information could be beneficial, 
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